var title_f41_48_42752="Excision ureth diverticulum";
var content_f41_48_42752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transvaginal excision of a small urethral diverticulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The forceps is on the diverticulum which has been dissected intact to the connection with the urethra just prior to transection. Additional Allis clamps have been placed on the vaginal epithelium to improve exposure. The white arrow points to the urethral catheter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert E Gutman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42752=[""].join("\n");
var outline_f41_48_42752=null;
var title_f41_48_42753="Zonal anatomy of prostate";
var content_f41_48_42753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Zonal anatomy of the prostate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transition zone and peripheral zone on (a) T2-weighted magnetic resonance imaging and (b) ultrasound.",
"    <div class=\"footnotes\">",
"     AFS: anterior fibromuscular stroma; PZ: peripheral zone; TZ: transition zone.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McLaughlin, PW, Troyer, S, Berri, S, et al. Functional anatomy of the prostate: Implications for treatment planning. Int J Radiation Oncology Biol Phys 2005; 63:479. Copyright &copy;2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42753=[""].join("\n");
var outline_f41_48_42753=null;
var title_f41_48_42754="Technetium Tc-99m succimer: Patient drug information";
var content_f41_48_42754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m succimer: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/61/29650?source=see_link\">",
"     see \"Technetium Tc-99m succimer: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13210341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DMSA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13374651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with a special imaging test of the kidneys.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13374650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560756",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to technetium Tc 99m succimer or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13374654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13374655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13374656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13374653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13374658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17087 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42754=[""].join("\n");
var outline_f41_48_42754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210341\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374651\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374650\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374654\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374655\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374656\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374653\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374658\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/61/29650?source=related_link\">",
"      Technetium Tc-99m succimer: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_48_42755="Diatrizoate meglumine: Patient drug information";
var content_f41_48_42755=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Diatrizoate meglumine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/0/14340?source=see_link\">",
"     see \"Diatrizoate meglumine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cystografin&reg;;",
"     </li>",
"     <li>",
"      Cystografin&reg; Dilute",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used before an x-ray or an alike test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to diatrizoate meglumine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a contrast dye allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an iodine allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11625 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42755=[""].join("\n");
var outline_f41_48_42755=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158941\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025980\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025979\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025983\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025984\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025986\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025982\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025987\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025988\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/0/14340?source=related_link\">",
"      Diatrizoate meglumine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_48_42756="Silver sulfadiazine: Patient drug information";
var content_f41_48_42756=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Silver sulfadiazine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10964?source=see_link\">",
"     see \"Silver sulfadiazine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9795?source=see_link\">",
"     see \"Silver sulfadiazine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Silvadene&reg;;",
"     </li>",
"     <li>",
"      SSD&trade;;",
"     </li>",
"     <li>",
"      Thermazene&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flamazine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to avoid or treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug to an infant younger than 2 months of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702924",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to silver sulfadiazine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant and near term.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear special gloves while putting this drug on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part and take off dead skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected part and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on 1 or 2 times a day or as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695338",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a dressing if needed.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11864 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42756=[""].join("\n");
var outline_f41_48_42756=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221120\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221121\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017326\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017325\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017330\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017331\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017333\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017328\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017329\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017334\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017335\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10964?source=related_link\">",
"      Silver sulfadiazine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9795?source=related_link\">",
"      Silver sulfadiazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_48_42757="Longitudinal erythronychia melanoma in situ";
var content_f41_48_42757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85710%7EDERM%2F85607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85710%7EDERM%2F85607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal erythronychia secondary to melanoma in situ",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal erythronychia secondary to squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42757=[""].join("\n");
var outline_f41_48_42757=null;
var title_f41_48_42758="Scabies infant foot";
var content_f41_48_42758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60206%7EDERM%2F56862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60206%7EDERM%2F56862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies, infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rash of scabies may be more diffuse in infants, spreading to the trunk and scalp in addition to the extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher, GR, Ludwig, S, Baskin, MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy;2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous and hyperpigmented papules and crusts are present on the foot of this child with scabies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42758=[""].join("\n");
var outline_f41_48_42758=null;
var title_f41_48_42759="Food allergy: Impact on health-related quality of life";
var content_f41_48_42759=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Food allergy: Impact on health-related quality of life",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/48/42759/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/48/42759/contributors\">",
"     Sally A Noone, RN, MSN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/48/42759/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/48/42759/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/48/42759/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/48/42759/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/48/42759/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 6 to 8 percent of children and up to 4 percent of adults in the United States (US) are affected by food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/1\">",
"     1",
"    </a>",
"    ]. Food allergic reactions are the leading cause of emergency department visits for anaphylaxis in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/2\">",
"     2",
"    </a>",
"    ]. The only therapy for food allergy is emergency treatment in the case of an accidental exposure that triggers a reaction. The mainstay of management of these patients is avoidance of the food(s) that causes the allergic reaction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=see_link\">",
"     \"Management of food allergy: Avoidance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23832?source=see_link\">",
"     \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients and families must be vigilant about food allergen avoidance in a variety of settings (eg, home, restaurants, schools, camps, social gatherings). The burden of avoidance and fear of an accidental exposure can increase anxiety and result in reduced health-related quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews questionnaires used to measure health-related quality of life (HRQL) and discusses the impact of food allergy on HRQL. A broader overview of HRQL assessment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4120?source=see_link\">",
"     \"Evaluation of health-related quality of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEALTH-RELATED QUALITY OF LIFE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality of life is defined by the World Health Organization (WHO) as \"an individual's perception of their position of life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/5\">",
"     5",
"    </a>",
"    ]. HRQL refers to a person's or group's perception of the effect of an illness and its therapy on their quality of life and daily functioning. HRQL has three components: social, psychological, and physical. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4120?source=see_link\">",
"     \"Evaluation of health-related quality of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two types of instruments exist to measure HRQL: generic and disease-specific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Both questionnaires aim to measure impairments that patients or their families, rather than health professionals, consider important. Patients can have similar levels of clinical impairment and yet have widely different measures of HRQL.",
"   </p>",
"   <p>",
"    Generic questionnaires are useful in comparing different diseases and are sensitive to comorbidities. One limitation of generic instruments is that they may miss small changes in a patient's impairment over time because they do not incorporate questions directly related to the specific disorder.",
"   </p>",
"   <p>",
"    In contrast, disease-specific instruments cannot be used to compare disease states or evaluate comorbidities. However, disease-specific instruments are more sensitive to changes in the illness of interest. Thus, they are more likely to detect changes that result from a treatment or intervention, or reveal differences in subgroups of patients with a particular disease. As examples, the impact of food allergy may vary depending upon factors related to type of food, number of food allergies, severity of symptoms, threshold amount of the food needed to trigger a reaction, age or gender of the patient, or cross-cultural differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Validated HRQL questionnaires can be used to not only identify the quality of life issues that patients and families living with food allergy struggle with, but can also identify the broader socioeconomic impact of food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/6\">",
"     6",
"    </a>",
"    ]. This information will lead to initiatives to mitigate the effects, including working with food manufacturers and the restaurant industry, educating the general public, and enacting legislative measures and regulatory interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERIC INSTRUMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of food allergy on HRQL was first examined using generic instruments. These questionnaires revealed significant fear, anxiety, and restrictions in day-to-day activities associated with food allergy, especially in children and their families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/9\">",
"     9",
"    </a>",
"    ]. In most cases, these effects were within the range expected for a potentially life-threatening disease. However, in some families the impact was great enough to interfere with normal psychosocial development of the child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/10\">",
"     10",
"    </a>",
"    ]. Findings from one small study suggested that food allergy has a greater impact on the quality of life (QOL) of the parents than the affected child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first well-designed study examining HRQL and food allergy was published in 2000. This study compared the quality of life and family relations of children and adults with peanut allergy to those with rheumatologic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/12\">",
"     12",
"    </a>",
"    ]. The study included 153 children and 37 adults with peanut allergy, and 69 children and 42 adults with rheumatologic disease. For both groups, age at recruitment was limited to less than 46 years to minimize comorbidity. The questionnaires used included a visual analog scale (VAS) adapted from the European Quality of Life Questionnaire and the Impact on Family Life Questionnaire (IFQ).",
"   </p>",
"   <p>",
"    The results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The parents of peanut allergic children reported that their children had significantly more disruption in their daily activities and greater impairment in the familial-social dimension of the IFQ compared with children with rheumatologic disease.",
"     </li>",
"     <li>",
"      Conversely, adults with a chronic rheumatologic disease reported more disruption in their family relations than adults with peanut allergy, although they reported comparable disruption to their quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A second study used the Children's Health Questionnaire (CHQ-PF50) to measure parental perceptions of physical and psychosocial functioning in families of children aged 5 to 18 years with food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The CHQ-PF50 measures children's health issues related to 12 domains of physical, emotional, and social functioning. An additional unvalidated allergy-related questionnaire was included.",
"   </p>",
"   <p>",
"    Questionnaires were sent to 400 members of the Food Allergy and Anaphylaxis Network, a lay organization for families living with food allergy. There was a response rate of 63 percent. Results of this study showed that childhood food allergy has a significant impact on quality of life for these families. It is possible that the study group was not entirely representative of all families of children with food allergy.",
"   </p>",
"   <p>",
"    The following measures showed reduced scores compared with healthy controls in the US population (a 10 point deficit is considered to be clinically relevant and a lower score indicates a lower quality of life):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      General health perception (59.3 versus 73.0)",
"     </li>",
"     <li>",
"      Emotional impact on the parent (68.1 versus 80.3)",
"     </li>",
"     <li>",
"      Limitation on family activities (73.9 versus 89.7)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lower scores were associated with concomitant atopic disease and greater number of foods avoided. In one area, family cohesion, higher scores were seen in families living with food allergy compared with healthy controls.",
"   </p>",
"   <p>",
"    A survey performed in the United Kingdom evaluated the quality of life of 20 children with peanut allergy (mean age nine years) compared with 20 children with type 1 diabetes mellitus (mean age 10.4 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/15\">",
"     15",
"    </a>",
"    ]. The inclusion criterion was an allergic reaction to peanuts or a hypoglycemic episode. Subjects were recruited from allergy and diabetes clinics or by mail from established clinic records. Two unvalidated questionnaires were used, one designed by the researchers (questionnaire 1) and one adapted from the Vespid Allergy Quality of Life Questionnaire (questionnaire 2). In addition, subjects were given a disposable camera to record how their quality of life was affected over a 24-hour period.",
"   </p>",
"   <p>",
"    Questionnaire response rate for both groups was 100 percent. Cameras were used and returned by 16 children with peanut allergy and 19 with insulin-dependent diabetes mellitus. Pictures taken were placed in categories: food, management, environment, physical activities, restaurant, away from home, and people. Overall, quality of life was more impaired in children with peanut allergy than with diabetes.",
"   </p>",
"   <p>",
"    The following results were found:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with peanut allergy reported a lower quality of life than children with diabetes (54.8 versus 46.4 for questionnaire 1, and 54.3 versus 34.5 for questionnaire 2). In this study, a higher score indicated a lower quality of life.",
"     </li>",
"     <li>",
"      Five children with peanut allergy reported that they were either very scared or extremely scared of accidentally eating peanuts, while children with diabetes indicated they were only moderately scared or less about having a hypoglycemic attack.",
"     </li>",
"     <li>",
"      Two of the children with peanut allergy reported to be scared of dying when they knew that peanuts were nearby. Children with diabetes commented on food restrictions, but none mentioned fear of death.",
"     </li>",
"     <li>",
"      Children with peanut allergy described being constantly aware of allergens and felt more threatened by potential hazards in their environment. They were more anxious about being away from home, especially eating away from home.",
"     </li>",
"     <li>",
"      Physical activities were restricted to a greater extent in children with peanut allergy than children with diabetes.",
"     </li>",
"     <li>",
"      All of the children with peanut allergy and 85 percent of the children with diabetes photographed food related issues.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 20 percent of schoolchildren and adolescents in Sweden suffer from perceived food hypersensitivity (eg, allergy or intolerance). A study was conducted to investigate the parent-reported HRQL in 220 families with a school-aged child considered to be food hypersensitive (response rate 74 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/16\">",
"     16",
"    </a>",
"    ]. Two questionnaires were used: a generic instrument, the CHQ-PF28, and a study-specific questionnaire including questions on allergy associated parameters.",
"   </p>",
"   <p>",
"    The authors found the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An important predictor of low HRQL was documented allergic disease (ie, asthma, eczema, rhinoconjunctivitis) in addition to food",
"      <span class=\"nowrap\">",
"       allergy/intolerance.",
"      </span>",
"      The higher the number of allergic diseases, the lower the physical HRQL for the child, the lower the parental HRQL, and the more disruption in family activities.",
"     </li>",
"     <li>",
"      Boys had a lower physical HRQL than girls.",
"     </li>",
"     <li>",
"      Children with siblings who also have food",
"      <span class=\"nowrap\">",
"       allergy/intolerance",
"      </span>",
"      had lower psychosocial HRQL. Parental HRQL was also lower when more than one child was involved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that the variance in the child's physical HRQL was explained in large part by the presence of other allergic disease. However, adverse food reactions, whether food allergy or intolerance, by themselves were associated with lower scores for the child's psychosocial HRQL, regardless of additional allergic disease.",
"   </p>",
"   <p>",
"    There are limited HRQL studies in adults with food allergy. A Dutch study examined the influence of food allergy on daily life in and outside the home in adults with peanut, tree nut,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fruit allergy (oropharyngeal symptoms at a minimum) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/17\">",
"     17",
"    </a>",
"    ]. Impact on quality of life was measured using a five-point scale. Sixty-three percent of patients rated their food allergy as influencing their daily life at home or outside the home to a very great, great, or important extent. There was no difference between patients with peanut-tree nut allergy only compared with patients with fruit allergy only.",
"   </p>",
"   <p>",
"    There are several differences between food allergy and chronic illnesses such as diabetes and rheumatologic disease. Although diabetes has a greater potential to cause long-term complications and impacts life expectancy, food allergy has a greater immediate impact on day to day functioning and quality of life. A daily insulin regimen to manage diabetes may be bothersome, but it gives patients some sense of control over their illness. Patients with food allergy live in a constant state of vigilance and uncertainty, because of fear of exposure to the allergen.",
"   </p>",
"   <p>",
"    Life-threatening events in food allergy are usually sudden in onset. The patient or",
"    <span class=\"nowrap\">",
"     parent/caregiver",
"    </span>",
"    is often the first-responder when an acute event occurs. This is another significant burden for parents and other adults responsible for the care of the affected child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DISEASE-SPECIFIC INSTRUMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to generic tools to measure HRQL, disease-specific questionnaires are more sensitive and responsive to issues specific to the disease under study. A number of the earlier studies discussed above used unvalidated food allergy-specific questionnaires in addition to generic instruments. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Generic instruments'",
"    </a>",
"    above.) Several food allergy specific questionnaires are now available, although most still require longitudinal validation.",
"   </p>",
"   <p>",
"    Disease-specific instruments have identified many HRQL issues confronted by patients and families with food allergy. These tools can identify differences between subgroups, such as children with multiple food allergies versus those with a single food allergy. Food allergy-specific questionnaires have not yet been used longitudinally to determine the impact of interventions on HRQL, although this is one of the major goals of these instruments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Food allergy quality of life - Parental burden (FAQL-PB)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first validated food allergy-specific questionnaire was developed to measure parental burden in families with a child with food allergy (FAQL-PB) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This instrument showed the ability to discriminate by disease burden. Parents whose children had greater than two food allergies were more affected than parents whose children had fewer allergies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/18\">",
"     18",
"    </a>",
"    ]. Poorer quality of life was also seen in caregivers who were more knowledgeable about food allergy, whose children were seen in the emergency department in the past year for food allergy, or who had children with milk or wheat allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many HRQL domains that affect families living with food allergy were identified during the development of this questionnaire [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family and social activities",
"     </li>",
"     <li>",
"      School and camp",
"     </li>",
"     <li>",
"      Social activities that involve food",
"     </li>",
"     <li>",
"      Vacation",
"     </li>",
"     <li>",
"      Eating in restaurants",
"     </li>",
"     <li>",
"      Finding appropriate childcare",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parents worried about health and nutritional concerns for their children and were concerned about treating a food-induced allergic reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/18\">",
"     18",
"    </a>",
"    ]. Feelings such as anxiety, frustration, and sadness were common among parents of children with food allergies. A consistent concern of caregivers was social limitations resulting from their child&rsquo;s food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A pilot study used the FAQL-PB to determine if a self-regulation intervention for parents of children with food allergies was effective in improving parental QOL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/20\">",
"     20",
"    </a>",
"    ]. The intervention addressed parental concerns, goals, and barriers and involved discussion of coping mechanisms and strategies to overcome barriers. Greater improvements were seen in the intervention group compared with the control group in 4 of 17 questionnaire factors that involved frustration, helplessness, anxiety, and confidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Food allergy impact scale (FAIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second food allergy-specific tool was designed to determine the impact of food allergy on the daily activities of children and their families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/21\">",
"     21",
"    </a>",
"    ]. The Food Allergy Impact Scale (FAIS) is a 32-item questionnaire. This scale is not validated.",
"   </p>",
"   <p>",
"    This instrument was tested on 101 caregivers of children with food allergy ages 8 months to 17 years recruited from a university-based allergy clinic (response rate 86 percent). Most surveys were completed during the clinic visit, providing information that this 15-minute survey can be incorporated into clinical practice.",
"   </p>",
"   <p>",
"    The study demonstrated that food allergy has a significant impact on the daily activities of children and their families and increases parental stress level. Specific findings from this work include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over 60 percent of parents indicated that food allergy significantly impacted meal preparation.",
"     </li>",
"     <li>",
"      Half of caregivers reported that food allergy affected family social activities.",
"     </li>",
"     <li>",
"      One-third of caregivers reported that food allergy affected their child's school attendance. Ten percent chose to home-school their child because of food allergy.",
"     </li>",
"     <li>",
"      The number of food allergies negatively correlated with activity scores.",
"     </li>",
"     <li>",
"      Approximately 40 percent of parents relayed that their child's food allergy had a significant impact on their level of stress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Food allergy parent questionnaire (FAPQ)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another study presented preliminary psychometric information on an 18-item questionnaire, the Food Allergy Parent Questionnaire (FAPQ), designed to assess parental adjustment to a child's food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/22\">",
"     22",
"    </a>",
"    ]. Items were based upon clinical experience working with food allergic children and their families. The goal was to screen a wide range of emotional and coping responses related to caring for a child with food allergies.",
"   </p>",
"   <p>",
"    A total of 221 parents of children up to 18 years of age with food allergy were recruited from a private allergy practice and local food allergy support groups (response rate 87 percent). Approximately 70 percent of children had more than one food allergy, and over half had a history of anaphylaxis.",
"   </p>",
"   <p>",
"    Parents responded as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most thought about their child's food allergy daily",
"     </li>",
"     <li>",
"      Half were frequently afraid for their child's safety because of the food allergy",
"     </li>",
"     <li>",
"      Most felt that they were in agreement with their",
"      <span class=\"nowrap\">",
"       spouse/partner",
"      </span>",
"      with regard to how to manage their child's food allergy and about half felt that they could depend upon their extended family to understand and help with the issue",
"     </li>",
"     <li>",
"      Most felt that their competence in managing their child's food allergy had improved since its onset",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Scores on the FAPQ showed small, yet statistically significant associations with several demographic and disease characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of anaphylaxis and greater number of food allergies were associated with higher scores on the parental",
"      <span class=\"nowrap\">",
"       anxiety/distress",
"      </span>",
"      and psychosocial impact subscales.",
"     </li>",
"     <li>",
"      Younger age of the child was associated with greater parental anxiety and distress. This was attributed to worry about the potential impact of food allergies on the child's health and development.",
"     </li>",
"     <li>",
"      Support group members scored significantly higher in areas of parental",
"      <span class=\"nowrap\">",
"       anxiety/distress,",
"      </span>",
"      psychosocial impact, and",
"      <span class=\"nowrap\">",
"       coping/competence",
"      </span>",
"      than those recruited from the private allergy practice, possibly because parents with a greater tendency toward anxiety are more likely to participate in support groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With further development, the FAPQ may be a practical tool to use in assessing needs of parents living with a child with food allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Food allergy quality of life questionnaire - Parent form (FAQLQ-PF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;An international group developed a \"parent form,\" \"child form,\" and \"teenager form\" to evaluate the impact of food allergy on quality of life from various perspectives. The \"parent form\" allowed parents to report their child's HRQL from the child's perspective as perceived by the parent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/23\">",
"     23",
"    </a>",
"    ]. This was in contrast to the questionnaires discussed above that measured a child's HRQL from the parent's perspective. The questionnaire contained three subscales: emotional impact, food anxiety, and social and dietary limitations.",
"   </p>",
"   <p>",
"    Results from this study suggest that anxiety related to the potential risk of a reaction due to accidental ingestion of a food allergen had a more profound impact on emotional and social aspects of a child's everyday life than the effect of an actual allergic reaction triggered by a food allergen.",
"   </p>",
"   <p>",
"    Differences were noted between subgroups but did not reach statistical significance. These included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Food anxiety was greater in younger children, aged 3 to 6 years",
"     </li>",
"     <li>",
"      School-aged children (6 to 12 years) were reported to have greater social and dietary limitations than younger children",
"     </li>",
"     <li>",
"      The overall impact on HRQL and the emotional impact subscale was greatest in boys 6 years of age and younger and girls 6 to 12 years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Findings from a longitudinal study of the validity and responsiveness of the FAQLQ-PF suggest that changes in food allergy management, such as food challenges, educational programs, or emerging treatments such as oral immunotherapy and anti IgE therapy, may alter HRQL. The authors identify the need to develop valid and reliable instruments to measure such changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Food allergy quality of life questionnaire - Child form (FAQLQ-CF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"child form\" and \"teenager form\" were the first food allergy-specific HRQL questionnaires developed for self-administration by children with food allergies. The \"child form\" was designed for children aged 8 to 12 years. This instrument distinguished between children with more than two food allergies and those with less, but was unable to discriminate between those with and without a history of anaphylaxis.",
"   </p>",
"   <p>",
"    The questionnaire was divided into subscales of areas most important to the HRQL in children with food allergy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergen avoidance (eg, not as easy to have a meal at a friend's house, explaining their food allergy when eating out)",
"     </li>",
"     <li>",
"      Risk of accidental exposure (eg, concerns about label reading, watching what foods they touch, people forgetting that they have a food allergy)",
"     </li>",
"     <li>",
"      Emotional impact (eg, fear of an accidental exposure, concern that the food allergy will never resolve)",
"     </li>",
"     <li>",
"      Dietary restrictions (eg, always having to watch what they eat, more limited in what they can eat, don't get anything when someone brings a special treat to school)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The three most important items related to impaired HRQL for children of this age were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"Must always watch what you eat\"",
"     </li>",
"     <li>",
"      \"The ingredients of a food change\"",
"     </li>",
"     <li>",
"      \"Can eat fewer things\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Food allergy quality of life questionnaire - Teenager form (FAQLQ-TF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"teenager form\" was the first disease-specific HRQL questionnaire for adolescents 13 to 17 years of age with food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/7\">",
"     7",
"    </a>",
"    ]. The FAQLQ-TF was written and validated in Dutch. It was translated into English and other European languages and these versions will also be validated.",
"   </p>",
"   <p>",
"    This instrument was able to distinguish between adolescents with more than two food allergies and those allergic to only one food, but was unable to discriminate between those with and without a history of anaphylaxis.",
"   </p>",
"   <p>",
"    Approximately two-thirds of the items on this questionnaire were identical to the \"child form,\" despite the separate development of these tools. In addition, the same three questions had the greatest impact on HRQL. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Food allergy quality of life questionnaire - Child form (FAQLQ-CF)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Investigation of construct validity using expectation of outcome (EO) questions revealed that the EO question \"chance of dying when accidentally exposed\" did not correlate with any of the \"teenager form\" items. Thus, fear of dying did not appear to be a significant component of HRQL in teenagers. This finding was consistent with other studies that have noted that adolescents felt their food-induced anaphylaxis was \"no big deal\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/25\">",
"     25",
"    </a>",
"    ]. Young adults with self-reported food allergy perceived their allergy to have less impact on their lives than others thought it would [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, other studies have shown that teenagers take greater risks with their food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/27\">",
"     27",
"    </a>",
"    ] and are at higher risk of death from food allergy than other age groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10091739\">",
"    <span class=\"h2\">",
"     Food allergy quality of life questionnaire - Teen form (FAQL-teen)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another QOL assessment tool was developed for adolescents in the United States. Adolescents who participated were most concerned about the limitations their food allergy placed on social activities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/29\">",
"     29",
"    </a>",
"    ]. This instrument may help in ascertaining social and emotional concerns and identifying teens in need of counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28858074\">",
"    <span class=\"h2\">",
"     Food allergy quality of life questionnaire &ndash; Adult form (FAQLQ-AF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The &ldquo;adult form&rdquo; was the first questionnaire developed to measure an adult&rsquo;s HRQL as it relates to food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/30\">",
"     30",
"    </a>",
"    ]. The form was written and validated in the Dutch language, and a subsequent online English version was validated in American adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/31\">",
"     31",
"    </a>",
"    ]. The greatest concerns for adults with food allergies included the inability to identify foods that are safe to eat and the need for improved diagnosis of food allergy. These findings are important for care providers, catering industries, and food manufacturers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Food allergy knowledge, attitudes, and beliefs questionnaires",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another validated set of questionnaires addresses food allergy knowledge, beliefs, and attitudes of clinicians, parents of children with food allergies, and the general public parents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/32-36\">",
"     32-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings from the parent focus groups held as part of the questionnaire development included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mothers found it difficult to entrust others with the care of their child. This led many mothers to quit working outside the home since they felt they were better able to keep their child safe than other caregivers.",
"     </li>",
"     <li>",
"      Marital tensions and conflict were common and stemmed from differences in the level of protection parents felt their child needed. Mothers tended to try to shield their child from any possible risk, whereas fathers did not want food allergy to limit a child's life experiences.",
"     </li>",
"     <li>",
"      There was also emotional tension due to extended family members' lack of understanding of necessary food allergen avoidance measures and the potential risk of a life-threatening reaction.",
"     </li>",
"     <li>",
"      Fear and guilt, as well as anxiety, were common emotions.",
"     </li>",
"     <li>",
"      Parents were concerned about the possible negative effects of parental hypervigilance on their child.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, results from the validated parent questionnaire revealed that two in five parents encountered hostility from other parents who were requested to accommodate their child&rsquo;s food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/36\">",
"     36",
"    </a>",
"    ]. Furthermore, another survey (primarily parents describing their children) found that one in four children and young adults with food allergy had been bullied, teased, or harassed because of their food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42759/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3705?source=see_link&amp;anchor=H132445#H132445\">",
"     \"Food allergy in schools and camps\", section on 'Bullying'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The burden of avoidance and fear of an accidental exposure can increase anxiety and result in reduced health-related quality of life (HRQL) for both patients with food allergies and their families. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The stresses that families living with food allergy experience are important aspects to explore in providing care. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Health-related quality of life'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Results from generic HRQL questionnaires reveal that the constant vigilance required for food allergen avoidance and fear of a life-threatening reaction cause significant anxiety and lead to restricted daily activities. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Generic instruments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are six validated food allergy-specific HRQL questionnaires. The FAQL-PB measures parental burden, the FAQLQ-PF evaluates effects of food allergy on the child as perceived by the parent. FAQLQ-CF and -TF and FAQLQ-teen are self-administered tools that measure the impact of food allergy on children (aged 8 to 12 years) and teenagers (aged 13 to 17 years), respectively. The FAQLQ-AF is a self-administered tool that measures the impact of food allergy on adults. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Disease-specific instruments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a greater negative impact on the quality of life of children and their families when the child has multiple food allergies. All activities involving potential exposure to food are affected (eg,",
"      <span class=\"nowrap\">",
"       school/daycare,",
"      </span>",
"      vacation, camp, dining out, social gatherings). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Disease-specific instruments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anxiety related to the potential risk of a reaction due to accidental ingestion of a food allergen appears to have a more profound impact on emotional and social aspects of a child's everyday life than the effect of an actual allergic reaction triggered by a food allergen. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Disease-specific instruments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fear and anxiety are the biggest issues for preschool aged children. Social and dietary limitations have the strongest impact on HRQL for school-aged children with food allergy. Food allergies have the least impact on HRQL in teenagers, although their lack of fear may put them at greater risk for a life-threatening reaction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Disease-specific instruments'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/1\">",
"      Sicherer SH, Sampson HA. 9. Food allergy. J Allergy Clin Immunol 2006; 117:S470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/2\">",
"      Sampson HA. Anaphylaxis and emergency treatment. Pediatrics 2003; 111:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/3\">",
"      Cummings AJ, Knibb RC, King RM, Lucas JS. The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: a review. Allergy 2010; 65:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/4\">",
"      Ravid NL, Annunziato RA, Ambrose MA, et al. Mental health and quality-of-life concerns related to the burden of food allergy. Immunol Allergy Clin North Am 2012; 32:83.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization (WHO). Measurement of quality of life in children. Geneva: Division of mental health, 1993 (Report).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/6\">",
"      de Blok BM, Vlieg-Boerstra BJ, Oude Elberink JN, et al. A framework for measuring the social impact of food allergy across Europe: a EuroPrevall state of the art paper. Allergy 2007; 62:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/7\">",
"      Flokstra-de Blok BM, DunnGalvin A, Vlieg-Boerstra BJ, et al. Development and validation of a self-administered Food Allergy Quality of Life Questionnaire for children. Clin Exp Allergy 2009; 39:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/8\">",
"      Flokstra-de Blok BM, van der Velde JL, Vlieg-Boerstra BJ, et al. Health-related quality of life of food allergic patients measured with generic and disease-specific questionnaires. Allergy 2010; 65:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/9\">",
"      Teufel M, Biedermann T, Rapps N, et al. Psychological burden of food allergy. World J Gastroenterol 2007; 13:3456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/10\">",
"      Klinnert MD, Robinson JL. Addressing the psychological needs of families of food-allergic children. Curr Allergy Asthma Rep 2008; 8:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/11\">",
"      Valentine AZ, Knibb RC. Exploring quality of life in families of children living with and without a severe food allergy. Appetite 2011; 57:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/12\">",
"      Primeau MN, Kagan R, Joseph L, et al. The psychological burden of peanut allergy as perceived by adults with peanut allergy and the parents of peanut-allergic children. Clin Exp Allergy 2000; 30:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/13\">",
"      Sicherer SH, Noone SA, Mu&ntilde;oz-Furlong A. The impact of childhood food allergy on quality of life. Ann Allergy Asthma Immunol 2001; 87:461.",
"     </a>",
"    </li>",
"    <li>",
"     Langraf J, Abetz L, Ware JE, Jr. The Child Health Questionnaire (CHQ). A User's Manual, 1st ed, The Health Institute, Boston 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/15\">",
"      Avery NJ, King RM, Knight S, Hourihane JO. Assessment of quality of life in children with peanut allergy. Pediatr Allergy Immunol 2003; 14:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/16\">",
"      Marklund B, Ahlstedt S, Nordstr&ouml;m G. Health-related quality of life in food hypersensitive schoolchildren and their families: parents' perceptions. Health Qual Life Outcomes 2006; 4:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/17\">",
"      Le TM, Lindner TM, Pasmans SG, et al. Reported food allergy to peanut, tree nuts and fruit: comparison of clinical manifestations, prescription of medication and impact on daily life. Allergy 2008; 63:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/18\">",
"      Cohen BL, Noone S, Mu&ntilde;oz-Furlong A, Sicherer SH. Development of a questionnaire to measure quality of life in families with a child with food allergy. J Allergy Clin Immunol 2004; 114:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/19\">",
"      Springston EE, Smith B, Shulruff J, et al. Variations in quality of life among caregivers of food allergic children. Ann Allergy Asthma Immunol 2010; 105:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/20\">",
"      Baptist AP, Dever SI, Greenhawt MJ, et al. A self-regulation intervention can improve quality of life for families with food allergy. J Allergy Clin Immunol 2012; 130:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/21\">",
"      Bollinger ME, Dahlquist LM, Mudd K, et al. The impact of food allergy on the daily activities of children and their families. Ann Allergy Asthma Immunol 2006; 96:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/22\">",
"      Lebovidge JS, Stone KD, Twarog FJ, et al. Development of a preliminary questionnaire to assess parental response to children's food allergies. Ann Allergy Asthma Immunol 2006; 96:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/23\">",
"      DunnGalvin A, de BlokFlokstra BM, Burks AW, et al. Food allergy QoL questionnaire for children aged 0-12 years: content, construct, and cross-cultural validity. Clin Exp Allergy 2008; 38:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/24\">",
"      DunnGalvin A, Cullinane C, Daly DA, et al. Longitudinal validity and responsiveness of the Food Allergy Quality of Life Questionnaire - Parent Form in children 0-12 years following positive and negative food challenges. Clin Exp Allergy 2010; 40:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/25\">",
"      Akeson N, Worth A, Sheikh A. The psychosocial impact of anaphylaxis on young people and their parents. Clin Exp Allergy 2007; 37:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/26\">",
"      Lyons AC, Forde EM. Food allergy in young adults: perceptions and psychological effects. J Health Psychol 2004; 9:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/27\">",
"      Sampson MA, Mu&ntilde;oz-Furlong A, Sicherer SH. Risk-taking and coping strategies of adolescents and young adults with food allergy. J Allergy Clin Immunol 2006; 117:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/28\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001; 107:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/29\">",
"      Resnick ES, Pieretti MM, Maloney J, et al. Development of a questionnaire to measure quality of life in adolescents with food allergy: the FAQL-teen. Ann Allergy Asthma Immunol 2010; 105:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/30\">",
"      Flokstra-de Blok BM, van der Meulen GN, DunnGalvin A, et al. Development and validation of the Food Allergy Quality of Life Questionnaire - Adult Form. Allergy 2009; 64:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/31\">",
"      Goossens NJ, Flokstra-de Blok BM, Vlieg-Boerstra BJ, et al. Online version of the food allergy quality of life questionnaire-adult form: validity, feasibility and cross-cultural comparison. Clin Exp Allergy 2011; 41:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/32\">",
"      Gupta RS, Kim JS, Barnathan JA, et al. Food allergy knowledge, attitudes and beliefs: focus groups of parents, physicians and the general public. BMC Pediatr 2008; 8:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/33\">",
"      Gupta RS, Kim JS, Springston EE, et al. Development of the Chicago Food Allergy Research Surveys: assessing knowledge, attitudes, and beliefs of parents, physicians, and the general public. BMC Health Serv Res 2009; 9:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/34\">",
"      Gupta RS, Kim JS, Springston EE, et al. Food allergy knowledge, attitudes, and beliefs in the United States. Ann Allergy Asthma Immunol 2009; 103:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/35\">",
"      Gupta RS, Springston EE, Kim JS, et al. Food allergy knowledge, attitudes, and beliefs of primary care physicians. Pediatrics 2010; 125:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/36\">",
"      Gupta RS, Springston EE, Smith B, et al. Food allergy knowledge, attitudes, and beliefs of parents with food-allergic children in the United States. Pediatr Allergy Immunol 2010; 21:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42759/abstract/37\">",
"      Lieberman JA, Weiss C, Furlong TJ, et al. Bullying among pediatric patients with food allergy. Ann Allergy Asthma Immunol 2010; 105:282.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2411 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-2110654F66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42759=[""].join("\n");
var outline_f41_48_42759=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEALTH-RELATED QUALITY OF LIFE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERIC INSTRUMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DISEASE-SPECIFIC INSTRUMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Food allergy quality of life - Parental burden (FAQL-PB)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Food allergy impact scale (FAIS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Food allergy parent questionnaire (FAPQ)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Food allergy quality of life questionnaire - Parent form (FAQLQ-PF)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Food allergy quality of life questionnaire - Child form (FAQLQ-CF)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Food allergy quality of life questionnaire - Teenager form (FAQLQ-TF)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10091739\">",
"      Food allergy quality of life questionnaire - Teen form (FAQL-teen)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28858074\">",
"      Food allergy quality of life questionnaire &ndash; Adult form (FAQLQ-AF)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Food allergy knowledge, attitudes, and beliefs questionnaires",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/1/4120?source=related_link\">",
"      Evaluation of health-related quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3705?source=related_link\">",
"      Food allergy in schools and camps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/48/18185?source=related_link\">",
"      Management of food allergy: Avoidance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_48_42760="Hyperthyroidism during pregnancy: Treatment";
var content_f41_48_42760=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hyperthyroidism during pregnancy: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/48/42760/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/48/42760/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/48/42760/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/48/42760/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/48/42760/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/48/42760/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/48/42760/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/48/42760/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and treatment of pregnant women with hyperthyroidism parallels that of nonpregnant women and men, but presents some unique problems. There are several important issues that must be considered when hyperthyroidism occurs during pregnancy. These include understanding the indications for treatment, the therapeutic options for pregnant women, and the goals of antithyroid drug therapy.",
"   </p>",
"   <p>",
"    The treatment of hyperthyroidism during pregnancy is presented here. The clinical manifestations, diagnosis, and causes of hyperthyroidism and other aspects of thyroid disease during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12871?source=see_link\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=see_link\">",
"     \"Overview of thyroid disease in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Endocrine Society and the American Thyroid Association have published clinical guidelines for the management of thyroid dysfunction during pregnancy that are similar to the approach outlined here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Treatment recommendations are predominantly based upon observational studies and clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21852089\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graves' disease and hCG-mediated hyperthyroidism are the most common causes of hyperthyroidism during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12871?source=see_link&amp;anchor=H12186870#H12186870\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\", section on 'Establishing the cause'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    hCG-mediated hyperthyroidism (gestational transient thyrotoxicosis) is usually transient and does",
"    <strong>",
"     not",
"    </strong>",
"    require treatment. Similarly, the thyroid hyperfunction in women with hyperemesis gravidarum usually does",
"    <strong>",
"     not",
"    </strong>",
"    require treatment because it is mild and subsides as hCG production falls (typically by 14 to 18 weeks gestation). Women with severe hyperemesis, however, require treatment of dehydration with intravenous fluids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/20/29002?source=see_link\">",
"     \"Treatment and outcome of nausea and vomiting of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnant women with subclinical (low TSH, normal free T4) and mild asymptomatic overt hyperthyroidism due to Graves&rsquo; disease may be followed with no treatment. This includes women with a low TSH and minimal elevation in total T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    total T3 ([&lt;1.5 times the upper limit of the nonpregnant normal] or minimal elevation in trimester-specific free T4). In women who are being monitored without therapy, we measure TSH, free T4 (if there is a trimester-specific reference range),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    total T4 or total T3 every four to six weeks.",
"   </p>",
"   <p>",
"    Women with symptomatic moderate to severe overt hyperthyroidism due to Graves&rsquo; disease or gestational trophoblastic disease require treatment of hyperthyroidism. This includes women with total T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    total T3 &gt;1.5 times the upper limit of the nonpregnant normal, or women with marked elevation in trimester-specific free T4 levels. Although hyperthyroidism due to gestational trophoblastic disease resolves with treatment of the underlying gestational trophoblastic disease and subsequent normalization of hCG levels, symptomatic women require treatment prior to surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4137?source=see_link&amp;anchor=H592559#H592559\">",
"     \"Nonthyroid surgery in the patient with thyroid disease\", section on 'Preoperative preparation for urgent surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21852102\">",
"    <span class=\"h2\">",
"     Therapeutic options",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic options for hyperthyroid women are limited because of the potential adverse fetal effects of the available treatments.",
"   </p>",
"   <p>",
"    Thionamides are the primary treatment of hyperthyroidism due to Graves&rsquo; or gestational trophoblastic disease. They are actively transported into the thyroid gland where they inhibit both the organification of iodine to tyrosine&nbsp;residues in thyroglobulin and the coupling of iodotyrosines. In addition, beta blockers, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , can be used to treat tachycardia and tremor. However, long-term treatment with beta blockers (longer than two to six weeks) should be avoided because of concerns regarding fetal growth retardation and hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radioiodine is absolutely contraindicated during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/7\">",
"     7",
"    </a>",
"    ]. Fetal thyroid tissue is present by 10 to 12 weeks and therefore can be ablated by radioiodine. Many experienced clinicians, however, have encountered one or two women inadvertently treated with radioiodine during early pregnancy; the anecdotal impression is that radioiodine given before about 8 to 10 weeks of pregnancy does not cause fetal hypothyroidism or birth defects. In one systematic review, the risks to the fetus were dependent upon the timing of exposure during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/8\">",
"     8",
"    </a>",
"    ]. Spontaneous miscarriage was more likely when exposure (100 mGy) occurred during the first two weeks (prior to implantation). Exposure during organogenesis (from two weeks gestation) may result in birth defects. After fetal thyroid has developed the capacity to capture iodine (12 to 14 weeks), there is a risk of fetal thyroid ablation and the attendant effects on neurocognitive development. If treatment is given during pregnancy, there needs to be full disclosure. Depending on the couple's wishes, termination of pregnancy might be considered.",
"   </p>",
"   <p>",
"    Thyroidectomy during pregnancy is rarely necessary but is an option for women who cannot tolerate thionamides because of allergy or agranulocytosis (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Surgery'",
"    </a>",
"    below). Plasmapheresis has also been used to rapidly control hyperthyroidism in women with trophoblastic disease and severe hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A good fetal and maternal outcome depends upon controlling the mother's hyperthyroidism. The goal of treatment is to maintain the mother's serum free T4 concentration at or just above the trimester-specific normal range for pregnancy using the lowest possible dose. If a trimester-specific reference range is not available, free T4 should be maintained in the high-normal range for nonpregnant women using the lowest drug dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/11\">",
"     11",
"    </a>",
"    ]. This requires assessment of thyroid function frequently (ie, at four-week intervals) with appropriate adjustment of medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers may be given to ameliorate the symptoms of moderate to severe hyperthyroidism in pregnant women. We typically start with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    25 to 50 mg daily.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    , 20 mg every six to eight hours, is an alternative option. The dose can be increased as needed to control symptoms. However, if possible, beta blockers should be weaned as soon as the hyperthyroidism is controlled by thionamides because occasional cases of neonatal growth restriction, hypoglycemia, respiratory depression, and bradycardia have been reported after maternal administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/4,5,12\">",
"     4,5,12",
"    </a>",
"    ]. There are no data directly comparing the effect of atenolol versus propranolol on birth weight. In a retrospective analysis, women with chronic hypertension who used atenolol in early (15 weeks gestation) compared with late (30 weeks gestation) pregnancy had significantly smaller babies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/4\">",
"     4",
"    </a>",
"    ]. There has been one report suggesting a higher rate of spontaneous abortion for hyperthyroid women treated with both a thionamide and propranolol compared with a thionamide alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/13\">",
"     13",
"    </a>",
"    ]. In most patients, beta blockers can and should be tapered and discontinued within two to six weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/275?source=see_link\">",
"     \"Beta blockers in the treatment of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21143?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of Graves' hyperthyroidism\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thionamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thionamides are recommended for treatment of moderate to severe hyperthyroidism complicating pregnancy. Available thionamides include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    (PTU),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    (MMI), and carbimazole (CBZ), which is completely metabolized to MMI.",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    (MMI) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    (PTU) probably cross the placenta with equal transfer kinetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/14\">",
"     14",
"    </a>",
"    ] and have similar effects on the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In one report of 77 newborns of euthyroid mothers treated with PTU or MMI, there were no significant differences in TSH concentrations measured in cord blood at birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/16\">",
"     16",
"    </a>",
"    ]. However, mean cord TSH levels were higher in neonates exposed to PTU, but not methimazole, compared to control neonates who were not exposed in utero to thionamides.",
"   </p>",
"   <p>",
"    Low thyroid function at birth is found in approximately one-half of neonates whose mothers received PTU or MMI during pregnancy and who had serum T4 concentrations within the normal (nonpregnant) range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/17\">",
"     17",
"    </a>",
"    ]. In spite of these observations, two studies reported that the IQ scores of children who were exposed to thionamides in utero (but were euthyroid at birth) were normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Possible teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     Methimazole",
"    </a>",
"    and carbimazole have been associated with possible teratogenic effects including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Case reports of aplasia cutis, a scalp defect, in newborns of mothers treated with (or exposed to) MMI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15864?source=see_link&amp;anchor=H19#H19\">",
"       \"Vesiculobullous and pustular lesions in the newborn\", section on 'Aplasia cutis congenita'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      More serious congenital malformations, such as tracheoesophageal fistulas, patent vitellointestinal duct, and choanal atresia, have been observed with maternal MMI and carbimazole, but not PTU use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/22-31\">",
"       22-31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the UK, spontaneous reporting of adverse drug reactions over a 47-year period found 57 cases with 97 anomalies for carbimazole, and only six cases with 11 anomalies for PTU; however, the relative use of these two drugs in pregnant women is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/30\">",
"     30",
"    </a>",
"    ]. In a population-based study from Taiwan, there was no increased risk of congenital anomalies among babies of hyperthyroid women treated with either PTU (n = 630 women) or methimazole (n = 73 women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/32\">",
"     32",
"    </a>",
"    ]. The small number of methimazole-treated women may have made this study underpowered to detect a teratogenic effect. In contrast, a Japanese study of pregnant women with Graves&rsquo; disease found that 50 of 1231 patients (4.1 percent) treated with methimazole, 12 of 1399 (1.9 percent) treated with PTU, and 40 of 1906 (2.1 percent) who did not receive antithyroid drugs had congenital malformations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/31\">",
"     31",
"    </a>",
"    ]. Methimazole was associated with a significant increase in aplasia cutis, omphalocele, and omphalomesenteric duct anomaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, PTU was considered the drug of choice throughout pregnancy for women with hyperthyroidism, because of concerns about the possible teratogenic effects of MMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, reports of severe PTU-related liver failure have now raised concerns about the routine use of PTU, including the use of PTU in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/34\">",
"     34",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     Methimazole",
"    </a>",
"    has also been associated with liver disease, but it is typically due to cholestatic dysfunction, not hepatocellular inflammation.",
"   </p>",
"   <p>",
"    We agree with the change in recommendations for antithyroid drugs as outlined by the American Thyroid Association, the Endocrine Society, and the US Food and Drug Administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/1,3,34,35\">",
"     1,3,34,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that PTU",
"      <strong>",
"       not",
"      </strong>",
"      be used as a first-line drug in children or adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41303?source=see_link&amp;anchor=H12#H12\">",
"       \"Pharmacology and toxicity of thionamides\", section on 'Hepatotoxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For pregnant women with hyperthyroidism, we suggest that PTU use be limited to the first trimester only. Although the teratogenic effects of MMI are not well proven, they are potentially serious and are likely confined to the first trimester during organogenesis. After the first trimester, the potential risk of PTU-associated hepatotoxicity, although extremely rare, is thought to outweigh any potential risks of MMI. Women who are taking MMI and learn they are pregnant should be switched to PTU at the time of the positive pregnancy test.",
"     </li>",
"     <li>",
"      In the second trimester, we suggest switching from PTU to an equivalent dose of MMI. Although the ratio of potencies of PTU and MMI is uncertain, clinical experience suggests that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      is 20 to 30 times as potent on a milligram to milligram basis. Therefore, 300 mg of PTU would be roughly equivalent to 10 or 15 mg of MMI. Thyroid function testing should be performed two to four weeks after switching to methimazole to be sure that a euthyroid state has been maintained.",
"     </li>",
"     <li>",
"      Subsequent monitoring of thyroid function should be performed every four weeks. Extra caution is necessary after switching from PTU to MMI to avoid maternal overtreatment and fetal hypothyroidism. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Dose and monitoring'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PTU-associated liver failure, which can occur at any time during the course of treatment, has a sudden onset and a rapidly progressive course. Therefore, routine monitoring of liver function is not currently suggested by the ATA and FDA. Patients should be advised to stop their medication and contact their clinician if they develop weakness, malaise, nausea and vomiting, jaundice, dark urine or light-colored stools.",
"   </p>",
"   <p>",
"    Some clinicians and their patients prefer to monitor liver function every four weeks when blood is being drawn to assess thyroid function. If this approach is chosen, PTU should be discontinued if serum transaminases are greater than three times the upper limit of normal. This approach has not been shown to reduce the risk of PTU-associated liver failure. Once the drug is discontinued, the patient should be followed closely with frequent transaminase measurements to be sure that they are returning to normal. If they progressively rise, immediate referral to a clinician with expertise in liver disease is recommended.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient develops a rash when switched to MMI, the drug should be stopped and PTU resumed.",
"     </li>",
"     <li>",
"      Autoimmune thyroid disease frequently ameliorates in the third trimester. Whenever possible, based on assessment of thyrotropin antibody measurements and thyroid function tests, thionamides should be tapered and potentially discontinued during the third trimester.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dose and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;To minimize the risk of hypothyroidism in the fetus, we give the lowest dose of thionamide (PTU 50 mg two to three times daily, MMI 5 to 10 mg daily, or carbimazole 5 to 15 mg daily) necessary to control thyroid function. However, in patients with severe hyperthyroidism, full initial doses may be required (PTU 100 mg three times per day) or MMI (10 to 30 mg daily) to control hyperthyroidism.",
"   </p>",
"   <p>",
"    Thyroid function tests (TSH and free T4 or total T4 if a trimester specific reference range is not available for free T4) should be obtained every four weeks and more frequently immediately after switching antithyroid drugs. Our goal is to maintain persistent but minimal mild hyperthyroidism in the mother in an attempt to prevent fetal hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/17\">",
"     17",
"    </a>",
"    ]. Transient central hypothyroidism may be seen in infants whose mothers had poorly controlled hyperthyroidism during pregnancy, presumably due to suppression of the fetal pituitary-thyroid axis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/36\">",
"     36",
"    </a>",
"    ]. On the other hand, overtreatment of maternal hyperthyroidism can cause fetal hypothyroidism and goiter.",
"   </p>",
"   <p>",
"    The thionamide dose should be adjusted monthly to maintain serum free T4 concentrations at or just above the upper limit of normal, using a trimester-specific reference range. If trimester&ndash;specific normal ranges are not available, free T4 should be maintained in the high-normal range for nonpregnant women, or total T4 up to 18",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (50 percent above the upper limit of normal for nonpregnant women), and serum TSH concentrations in the low-normal or suppressed range. Serum TSH levels may remain low or undetectable throughout pregnancy.",
"   </p>",
"   <p>",
"    Ultimately, low doses of PTU or MMI (eg, 50 mg twice daily or less for PTU; 2.5 to 5 mg a day for MMI) may be all that is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/37\">",
"     37",
"    </a>",
"    ]. It is possible to discontinue the thionamide during the third trimester in at least one-third of women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/37\">",
"     37",
"    </a>",
"    ]; the amelioration of hyperthyroidism as pregnancy progresses is due to a fall in serum TSH receptor-stimulating antibody concentrations or, rarely, a rise in TSH receptor-blocking antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. However, Graves' hyperthyroidism can worsen postpartum. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Postpartum issues'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Monitoring throughout pregnancy is important because maternal hyperthyroidism in the third trimester may increase the risk of low birth weight (independent of the risk of neonatal Graves' disease). As an example, in a study of 181 women with a current or past history of hyperthyroidism, the risk of low birth weight was increased fourfold in the 35 women who had clinical and biochemical evidence of hyperthyroidism in the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Nursing",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTU is less soluble than MMI and is more bound to plasma proteins, whereas MMI is free in serum, so that relatively more MMI reaches the infant via breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/41\">",
"     41",
"    </a>",
"    ]. However, the doses of MMI are lower, so the actual milk levels are not that different. Nonetheless, there is little difference in serum thyroid hormone concentrations or thyroid function in infants of mothers given moderate doses of either drug. As an example, in a study of 139 mothers taking up to 20 mg MMI daily, thyroid function, growth, and development of their breast-fed infants were normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/42\">",
"     42",
"    </a>",
"    ]. Similar results were seen in a study of mothers taking PTU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has yet to be a report of agranulocytosis in an infant who was nursed by a woman taking PTU or MMI.",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    and PTU have been rated as safe for nursing mothers by the American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/44\">",
"     44",
"    </a>",
"    ]. However, given the concerns about potential PTU-associated hepatotoxicity, we suggest methimazole rather than PTU for nursing mothers. Methimazole should be administered following a feeding in divided doses. When the maternal dose of MMI is &gt;20 mg daily, infants should have thyroid function tests assessed after one and three months.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     T4 administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not recommend the use of T4 with thionamide therapy during pregnancy. Little T4 crosses the placenta, making it more difficult to determine the minimal dose of thionamide needed to control hyperthyroidism in the mother.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2274984\">",
"    <span class=\"h2\">",
"     Iodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not generally recommend the use of pharmacologic doses of iodine in pregnant women, but its short-term use could be considered in patients being prepared for thyroidectomy when thionamides are contraindicated. One study of 35 women with mild to moderate Graves' hyperthyroidism suggested that low doses of iodine are safe during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/45\">",
"     45",
"    </a>",
"    ]. Prolonged high-dose iodine therapy, however, can cause fetal goiter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroidectomy during pregnancy may be necessary in women with Graves&rsquo; disease who cannot tolerate thionamides because of allergy or agranulocytosis. The indications for surgery are similar to those in nonpregnant women and men. Surgery during pregnancy, however, is associated with an increased risk of spontaneous abortion or premature delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/47\">",
"     47",
"    </a>",
"    ] and significantly higher rates of surgical complications than nonpregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/48\">",
"     48",
"    </a>",
"    ]. These risks are minimized by operating during the second trimester. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15482?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to thyroidectomy, pregnant women with intolerance to thionamides should be pretreated with beta-blockers (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ) and a short course (ie, 7 to 10 days) of potassium iodine solution (35 to 50 mg iodine per drop, 1 to 3 drops daily). Iodine lowers serum thyroid hormone concentrations acutely and, in addition, decreases thyroid gland vascularity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/8/12424?source=see_link&amp;anchor=H6#H6\">",
"     \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\", section on 'Preoperative preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FETAL HYPERTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 1 to 5 percent of mothers with hyperthyroidism caused by Graves' disease (active or treated) have neonates (or fetuses) with hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/49\">",
"     49",
"    </a>",
"    ]. Although rare, it can be severe, even life threatening, and have deleterious effects on neural development.",
"   </p>",
"   <p>",
"    High fetal heart rate (&gt;160",
"    <span class=\"nowrap\">",
"     beats/minute),",
"    </span>",
"    fetal goiter, advanced bone age, poor growth, and craniosynostosis are manifestations of fetal hyperthyroidism. Cardiac failure and hydrops may occur with severe disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2275231\">",
"    <span class=\"h2\">",
"     Measurement of maternal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of maternal serum TSH receptor antibodies (TRAb) during the third trimester (24 to 28 weeks) helps to predict which infants are at higher risk for development of fetal and neonatal Graves' hyperthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The most readily available (and least expensive) assays are measurements of TSH-binding inhibitory antibodies in receptor assays (thyrotropin binding inhibitory immunoglobulin [TBII]). Although TBII assays do not indicate biologic activity, women with Graves' disease usually have stimulatory antibodies and the fetus or infant is more likely to have Graves' hyperthyroidism when the maternal value is more than three to five times the upper limit of normal. TRAb can also be detected by the thyroid stimulating immunoglobulin (TSI) assay, which measures biologic activity through generation of cyclic AMP.",
"   </p>",
"   <p>",
"    In pregnant women with a past or present history of Graves&rsquo; disease, we routinely check serum TRAb at 20 to 24 weeks gestation. If TRAb levels are over three times the upper limit of normal, fetal monitoring is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;All fetuses of women with Graves' disease should be monitored for signs of fetal thyrotoxicosis by determination of fetal heart rate and assessment of fetal growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/11\">",
"     11",
"    </a>",
"    ]. Fetal ultrasound monitoring should be performed in pregnant women with active Graves&rsquo; hyperthyroidism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    women with serum TRAb levels greater than two to three times the upper limit of normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/50\">",
"     50",
"    </a>",
"    ]. In one report, half of the goiters associated with fetal hyperthyroidism had central color flow Doppler versus none of the goiters associated with fetal hypothyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Fetal blood sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal blood for thyroid function tests can be obtained by percutaneous umbilical vein sampling after 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]; however, since this procedure is associated with a 1 to 2 percent risk of fetal loss it should",
"    <strong>",
"     not",
"    </strong>",
"    be done routinely in all pregnant women with Graves' disease.",
"   </p>",
"   <p>",
"    Fetal blood sampling can provide useful clinical information when fetal thyroid function is uncertain. As an example, in one study of 24 pregnancies (26 fetuses) among 18 mothers with Graves' disease, fetal blood sampling was performed when maternal anti-TSH receptor antibody levels were high or there were sonographic signs of fetal thyroid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/53\">",
"     53",
"    </a>",
"    ]. Five fetuses were found to be either hypothyroid (n = 3) or hyperthyroid (n = 2).",
"   </p>",
"   <p>",
"    In view of the risks of umbilical vein sampling, this procedure should be considered only when fetal goiter is present on ultrasound, and there is clinical uncertainty as to whether the fetus is hyperthyroid or hypothyroid because of maternal thionamide treatment.",
"   </p>",
"   <p>",
"    In these situations, knowledge of fetal thyroid status and medical intervention can improve",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    outcome and thus justify the risk of the procedure, which should only be performed by experienced obstetricians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thionamides may be given to mothers, regardless of maternal thyroid status, to treat the hyperthyroid fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neonatal hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The topic of neonatal hyperthyroidism is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/97?source=see_link\">",
"     \"Evaluation and management of neonatal Graves' disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40696?source=see_link\">",
"     \"Thyroid physiology and screening in preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     POSTPARTUM ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum hyperthyroidism may be due to postpartum thyroiditis or to an exacerbation of Graves&rsquo; disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of thyroid disease in pregnancy\", section on 'Postpartum thyroid dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/248?source=see_link\">",
"     \"Postpartum thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with Graves' disease who have been treated during pregnancy need careful monitoring during the postpartum period, as they may experience an exacerbation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/55\">",
"     55",
"    </a>",
"    ]. In addition, women with Graves' who have been in remission are at risk for having a relapse during this period. This was illustrated in a study of 150 women with Graves' disease in remission after antithyroid drug therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42760/abstract/56\">",
"     56",
"    </a>",
"    ]. Of the 25 women who had a subsequent pregnancy, 21 (84 percent) experienced a relapse, compared with 70 of 125 (56 percent) who did not have a pregnancy. The risk of relapse appeared to be related to the postpartum period rather than the pregnancy itself, as 20 of the 21 relapses occurred four to eight months postpartum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/58/13219?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with symptomatic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      moderate to severe overt hyperthyroidism due to Graves&rsquo; or gestational trophoblastic disease require therapy for the treatment of hyperthyroidism. Pregnant women with subclinical (low TSH, normal free T4) and asymptomatic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mild overt hyperthyroidism may be followed with no treatment. In women who are being monitored without therapy, we measure TSH and free T4 every four to six weeks. (See",
"      <a class=\"local\" href=\"#H21852089\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assuming there are no contraindications to its use, we suggest using a beta blocker for pregnant women with moderate to severe hyperthyroidism and hyperadrenergic symptoms (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Beta blockers'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/275?source=see_link\">",
"       \"Beta blockers in the treatment of hyperthyroidism\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      However, they should be given only to women who have many symptoms because occasional cases of fetal growth restriction, hypoglycemia, respiratory depression, and bradycardia have been reported after maternal administration.",
"      <br/>",
"      <br/>",
"      We typically start with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      25 to 50 mg daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      20 mg three to four times daily.",
"     </li>",
"     <li>",
"      For women with moderate to severe hyperthyroidism complicating pregnancy, we suggest a thionamide as our first choice of treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Thionamides'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We suggest using PTU rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      in the first trimester (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) and switching to methimazole at the start of the second trimester (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Choice of drug'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Thyroid function should be monitored monthly to maintain serum free T4 concentrations in the high-normal range and serum TSH concentrations in the low-normal or suppressed range. We try to limit the dose of PTU to 50 mg twice daily or less and MMI to doses of 5 to 10 mg per day or less; higher doses (eg, doses in excess of 200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      can result in fetal goiter and hypothyroidism. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Dose and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest thyroidectomy in hyperthyroid women during pregnancy only when thionamides are not tolerated because of allergy or agranulocytosis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Surgery'",
"      </a>",
"      above.) Such women should be treated with a short course (7 to 10 days) of beta blockers and iodine in preparation for thyroidectomy.",
"     </li>",
"     <li>",
"      We suggest not administering pharmacologic doses of iodine for long-term use because chronic use can cause fetal goiter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2274984\">",
"       'Iodine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radioiodine therapy for pregnant women with hyperthyroidism is absolutely contraindicated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17500759\">",
"    <span class=\"h2\">",
"     Fetal monitoring",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All fetuses of women with Graves' disease should be monitored for signs of fetal thyrotoxicosis by determination of fetal heart rate and assessment of fetal growth. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Fetal hyperthyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If fetal thyrotoxicosis is suspected, we suggest prenatal sonography to rule out fetal goiter. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the potential risk of fetal loss with fetal blood sampling, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      performing this procedure routinely in pregnant women with Graves' disease. Specific indications for fetal blood sampling are outlined above. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Fetal blood sampling'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/1\">",
"      Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/2\">",
"      Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/3\">",
"      De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/4\">",
"      Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999; 12:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/5\">",
"      Lip GY, Beevers M, Churchill D, et al. Effect of atenolol on birth weight. Am J Cardiol 1997; 79:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/6\">",
"      Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 1990; 301:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/7\">",
"      Stoffer SS, Hamburger JI. Inadvertent 131I therapy for hyperthyroidism in the first trimester of pregnancy. J Nucl Med 1976; 17:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/8\">",
"      Hyer SL, Pratt B, Newbold K, Hamer CL. Outcome of Pregnancy After Exposure to Radioiodine In Utero. Endocr Pract 2011; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/9\">",
"      Adali E, Yildizhan R, Kolusari A, et al. The use of plasmapheresis for rapid hormonal control in severe hyperthyroidism caused by a partial molar pregnancy. Arch Gynecol Obstet 2009; 279:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/10\">",
"      Azezli A, Bayraktaroglu T, Topuz S, Kalayoglu-Besisik S. Hyperthyroidism in molar pregnancy: rapid preoperative preparation by plasmapheresis and complete improvement after evacuation. Transfus Apher Sci 2007; 36:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/11\">",
"      American College of Obstetricians and Gynecologists.. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001). Thyroid disease in pregnancy. Obstet Gynecol 2002; 100:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/12\">",
"      Rubin PC. Current concepts: beta-blockers in pregnancy. N Engl J Med 1981; 305:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/13\">",
"      Sherif IH, Oyan WT, Bosairi S, Carrascal SM. Treatment of hyperthyroidism in pregnancy. Acta Obstet Gynecol Scand 1991; 70:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/14\">",
"      Mortimer RH, Cannell GR, Addison RS, et al. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab 1997; 82:3099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/15\">",
"      Roti E, Minelli R, Salvi M. Clinical review 80: Management of hyperthyroidism and hypothyroidism in the pregnant woman. J Clin Endocrinol Metab 1996; 81:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/16\">",
"      Momotani N, Noh JY, Ishikawa N, Ito K. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab 1997; 82:3633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/17\">",
"      Momotani N, Noh J, Oyanagi H, et al. Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status. N Engl J Med 1986; 315:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/18\">",
"      Burrow GN, Klatskin EH, Genel M. Intellectual development in children whose mothers received propylthiouracil during pregnancy. Yale J Biol Med 1978; 51:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/19\">",
"      Eisenstein Z, Weiss M, Katz Y, Bank H. Intellectual capacity of subjects exposed to methimazole or propylthiouracil in utero. Eur J Pediatr 1992; 151:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/20\">",
"      Van Dijke CP, Heydendael RJ, De Kleine MJ. Methimazole, carbimazole, and congenital skin defects. Ann Intern Med 1987; 106:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/21\">",
"      Mart&iacute;nez-Fr&iacute;as ML, Cereijo A, Rodr&iacute;guez-Pinilla E, Urioste M. Methimazole in animal feed and congenital aplasia cutis. Lancet 1992; 339:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/22\">",
"      Bowman P, Osborne NJ, Sturley R, Vaidya B. Carbimazole embryopathy: implications for the choice of antithyroid drugs in pregnancy. QJM 2012; 105:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/23\">",
"      Di Gianantonio E, Schaefer C, Mastroiacovo PP, et al. Adverse effects of prenatal methimazole exposure. Teratology 2001; 64:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/24\">",
"      Johnsson E, Larsson G, Ljunggren M. Severe malformations in infant born to hyperthyroid woman on methimazole. Lancet 1997; 350:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/25\">",
"      Wilson LC, Kerr BA, Wilkinson R, et al. Choanal atresia and hypothelia following methimazole exposure in utero: a second report. Am J Med Genet 1998; 75:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/26\">",
"      Foulds N, Walpole I, Elmslie F, Mansour S. Carbimazole embryopathy: an emerging phenotype. Am J Med Genet A 2005; 132A:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/27\">",
"      Wing DA, Millar LK, Koonings PP, et al. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol 1994; 170:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/28\">",
"      Clementi M, Di Gianantonio E, Pelo E, et al. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet 1999; 83:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/29\">",
"      Rosenfeld H, Ornoy A, Shechtman S, Diav-Citrin O. Pregnancy outcome, thyroid dysfunction and fetal goitre after in utero exposure to propylthiouracil: a controlled cohort study. Br J Clin Pharmacol 2009; 68:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/30\">",
"      Bowman P, Vaidya B. Suspected Spontaneous Reports of Birth Defects in the UK Associated with the Use of Carbimazole and Propylthiouracil in Pregnancy. J Thyroid Res 2011; 2011:235130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/31\">",
"      Yoshihara A, Noh J, Yamaguchi T, et al. Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab 2012; 97:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/32\">",
"      Chen CH, Xirasagar S, Lin CC, et al. Risk of adverse perinatal outcomes with antithyroid treatment during pregnancy: a nationwide population-based study. BJOG 2011; 118:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/33\">",
"      Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007; 92:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/34\">",
"      Bahn RS, Burch HS, Cooper DS, et al. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009; 19:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/35\">",
"      Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. J Clin Endocrinol Metab 2009; 94:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/36\">",
"      Sheffield JS, Cunningham FG. Thyrotoxicosis and heart failure that complicate pregnancy. Am J Obstet Gynecol 2004; 190:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/37\">",
"      Hamburger JI. Diagnosis and management of Graves' disease in pregnancy. Thyroid 1992; 2:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/38\">",
"      Salvi M, How J. Pregnancy and autoimmune thyroid disease. Endocrinol Metab Clin North Am 1987; 16:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/39\">",
"      Kung AW, Lau KS, Kohn LD. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy. J Clin Endocrinol Metab 2001; 86:3647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/40\">",
"      Phoojaroenchanachai M, Sriussadaporn S, Peerapatdit T, et al. Effect of maternal hyperthyroidism during late pregnancy on the risk of neonatal low birth weight. Clin Endocrinol (Oxf) 2001; 54:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/41\">",
"      Kampmann JP, Johansen K, Hansen JM, Helweg J. Propylthiouracil in human milk. Revision of a dogma. Lancet 1980; 1:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/42\">",
"      Azizi F, Khoshniat M, Bahrainian M, Hedayati M. Thyroid function and intellectual development of infants nursed by mothers taking methimazole. J Clin Endocrinol Metab 2000; 85:3233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/43\">",
"      Momotani N, Yamashita R, Makino F, et al. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin Endocrinol (Oxf) 2000; 53:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/44\">",
"      American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/45\">",
"      Momotani N, Hisaoka T, Noh J, et al. Effects of iodine on thyroid status of fetus versus mother in treatment of Graves' disease complicated by pregnancy. J Clin Endocrinol Metab 1992; 75:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/46\">",
"      Senior B, Chernoff HL. Iodide goiter in the newborn. Pediatrics 1971; 47:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/47\">",
"      Roti, E, Minelli, R, Gardini, E, et al. Controversies in the treatment of thyrotoxicosis. Adv Endocrinol Metab 1994; 5:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/48\">",
"      Kuy S, Roman SA, Desai R, Sosa JA. Outcomes following thyroid and parathyroid surgery in pregnant women. Arch Surg 2009; 144:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/49\">",
"      Zimmerman D. Fetal and neonatal hyperthyroidism. Thyroid 1999; 9:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/50\">",
"      Luton D, Le Gac I, Vuillard E, et al. Management of Graves' disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab 2005; 90:6093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/51\">",
"      Peleg D, Cada S, Peleg A, Ben-Ami M. The relationship between maternal serum thyroid-stimulating immunoglobulin and fetal and neonatal thyrotoxicosis. Obstet Gynecol 2002; 99:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/52\">",
"      Huel C, Guibourdenche J, Vuillard E, et al. Use of ultrasound to distinguish between fetal hyperthyroidism and hypothyroidism on discovery of a goiter. Ultrasound Obstet Gynecol 2009; 33:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/53\">",
"      Nachum Z, Rakover Y, Weiner E, Shalev E. Graves' disease in pregnancy: prospective evaluation of a selective invasive treatment protocol. Am J Obstet Gynecol 2003; 189:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/54\">",
"      Kilpatrick S. Umbilical blood sampling in women with thyroid disease in pregnancy: Is it necessary? Am J Obstet Gynecol 2003; 189:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/55\">",
"      Amino N, Tanizawa O, Mori H, et al. Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves' disease. J Clin Endocrinol Metab 1982; 55:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42760/abstract/56\">",
"      Rotondi M, Cappelli C, Pirali B, et al. The effect of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab 2008; 93:3985.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7884 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42760=[""].join("\n");
var outline_f41_48_42760=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21852089\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21852102\">",
"      Therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thionamides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Possible teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dose and monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Nursing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      T4 administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2274984\">",
"      Iodine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FETAL HYPERTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2275231\">",
"      Measurement of maternal antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neonatal hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      POSTPARTUM ISSUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17500759\">",
"      Fetal monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/275?source=related_link\">",
"      Beta blockers in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/97?source=related_link\">",
"      Evaluation and management of neonatal Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12871?source=related_link\">",
"      Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15482?source=related_link\">",
"      Management of pregnant women undergoing nonobstetric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/2/4137?source=related_link\">",
"      Nonthyroid surgery in the patient with thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/58/13219?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41303?source=related_link\">",
"      Pharmacology and toxicity of thionamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/248?source=related_link\">",
"      Postpartum thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/8/12424?source=related_link\">",
"      Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40696?source=related_link\">",
"      Thyroid physiology and screening in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/20/29002?source=related_link\">",
"      Treatment and outcome of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15864?source=related_link\">",
"      Vesiculobullous and pustular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_48_42761="Intraamniotic infection (chorioamnionitis)";
var content_f41_48_42761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intraamniotic infection (chorioamnionitis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/48/42761/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/48/42761/contributors\">",
"     Alan Thevenet N Tita, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/48/42761/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/48/42761/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/48/42761/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/48/42761/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/48/42761/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraamniotic infection (IAI) refers to infection of the amniotic fluid, membranes, placenta,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decidua. Other terms that have been used to describe this condition include chorioamnionitis, amnionitis, and amniotic fluid infection. Based on the presence or absence of overt clinical signs and the results of diagnostic tests, IAI may be subgrouped into clinical or subclinical infection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histologic chorioamnionitis (which may be noninfectious).",
"   </p>",
"   <p>",
"    IAI is a cause of maternal febrile morbidity in the peripartum period. It is associated with 20 to 40 percent of cases of early neonatal sepsis and pneumonia. In addition, a growing body of research has suggested that an exuberant fetal immune response to IAI is associated with white matter brain injury and cerebral palsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21512?source=see_link\">",
"     \"Neonatal pneumonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41768?source=see_link\">",
"     \"Epidemiology and etiology of cerebral palsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of IAI in the US population varies widely among publications, but consistently shows a decline as pregnancy advances toward term. The variation in incidence is due to several factors, including differences in ascertainment (prospective studies report higher rates than retrospective studies), differences in prevalence of risk factors in the populations studied, use of different diagnostic criteria (eg, clinical versus histologic), and temporal changes in obstetric practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preterm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of IAI is highest in preterm deliveries. In one review, the incidence of IAI in women with PROM at less than 27 weeks of gestation, 28 to 36 weeks of gestation, and term was 41, 15, and 2 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/5\">",
"     5",
"    </a>",
"    ]. IAI is associated with one-third of cases of preterm labor with intact membranes and is present in 40 percent of women with preterm premature rupture of membranes (PROM) admitted with contractions and 75 percent of those who develop labor after admission for preterm PROM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=see_link\">",
"     \"Pathogenesis of spontaneous preterm birth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Term",
"    </span>",
"    &nbsp;&mdash;&nbsp;IAI typically occurs in the setting of labor and membrane rupture, complicating approximately 2 to 4 percent of term deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/5\">",
"     5",
"    </a>",
"    ]. As many as 12 percent of women who undergo a primary cesarean at term after labor has begun have clinically-diagnosed IAI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several obstetric factors have been associated with IAI, including nulliparity, spontaneous labor, longer length of labor and membrane rupture, multiple digital vaginal examinations (especially with ruptured membranes), meconium-stained amniotic fluid, internal fetal or uterine monitoring, and presence of genital tract pathogens (eg, sexually transmitted infections, group B Streptococcus, bacterial vaginosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/3,8-13\">",
"     3,8-13",
"    </a>",
"    ]. Longer length of labor and length of ruptured membranes appear to be important risk factors, whereas an increasing number of digital examinations may be a consequence of longer labor rather than an independent risk factor, particularly prior to membrane rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/14\">",
"     14",
"    </a>",
"    ]. Multiparous patients are at low risk of IAI regardless of obstetric practice or risk factors. &nbsp;",
"   </p>",
"   <p>",
"    It is noteworthy that IAI can be either a risk factor for, or a result of, preterm labor or PROM, particularly at early gestational ages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;IAI is polymicrobial, primarily due to ascending colonization or infection; amniotic fluid culture in pregnancies complicated by IAI reveals multiple organisms from the vaginal flora (",
"    <a class=\"graphic graphic_table graphicRef66106 \" href=\"mobipreview.htm?43/32/44555\">",
"     table 1",
"    </a>",
"    ). Two-thirds of women with IAI have at least two isolates per specimen of amniotic fluid. Regardless of gestational age, genital mycoplasmas (ureaplasma and mycoplasma species) are the most common isolates. Anaerobes (including Gardnerella vaginalis), enteric gram-negative bacilli and group B streptococcus GBS are other frequent pathogens. Anaerobes appear to be more frequently involved in preterm IAI than term IAI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/15\">",
"     15",
"    </a>",
"    ]. Genital mycoplasmas are highly prevalent (&gt;70 percent) in the lower genital tract and their pathogenicity is controversial. For this reason, some authors attribute their isolation from patients with IAI to contamination or colonization from the lower tract, rather than a true infection. However, as data accrue, there is increasing support of their pathogenicity, including induction of a robust inflammatory response with clinical consequences for both mother and neonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical IAI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically, the essential criterion for diagnosis of IAI is maternal fever, which is a manifestation of systemic inflammation. Other criteria are insensitive.",
"   </p>",
"   <p>",
"    For clinical research, the diagnosis of IAI is typically based upon the presence of maternal fever of greater than 38 degrees C (100.4 F)",
"    <strong>",
"     and",
"    </strong>",
"    at least two of the following conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maternal leukocytosis (greater than 15,000",
"      <span class=\"nowrap\">",
"       cells/cubic",
"      </span>",
"      millimeter)",
"     </li>",
"     <li>",
"      Maternal tachycardia (greater than 100",
"      <span class=\"nowrap\">",
"       beats/minute)",
"      </span>",
"     </li>",
"     <li>",
"      Fetal tachycardia (greater than 160",
"      <span class=\"nowrap\">",
"       beats/minute)",
"      </span>",
"     </li>",
"     <li>",
"      Uterine tenderness",
"     </li>",
"     <li>",
"      Foul odor of the amniotic fluid",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The criteria for temperature, maternal heart rate, and fetal heart rate exceed the 90 to 95th percentile for normal pregnancies and the white blood cell (WBC) count exceeds the 80th percentile. These thresholds are associated with higher rates of neonatal and maternal morbidity and, in preterm gestations, define a population whose amniotic fluid contains higher concentrations of organisms (&gt;100 colony forming",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    of bacteria) and high-virulence isolates (group B Streptococcus, aerobic gram negative rods, anaerobes, and Mycoplasma hominis).",
"   </p>",
"   <p>",
"    Individual signs and symptoms are less specific for IAI. For example, maternal tachycardia may be physiologic or related to pain, epidural anesthesia, or medications (ephedrine); fetal tachycardia may be due to maternal medication or fetal hypoxemia; and uterine pain and tenderness also occur with placental abruption. On average, maternal WBC is higher in the presence of infection, but high values are frequently found in the absence of overt infection (eg, in association with labor or antenatal corticosteroids); therefore, routine serial monitoring of WBC in the setting of preterm membrane rupture is neither predictive nor cost-effective. However, when clinical concern about infection is high, leukocytosis (especially when accompanied by a left shift or bandemia) supports the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1956327\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differential diagnosis includes labor (which can cause leukocytosis, tachycardia, uterine tenderness, and fever [if is the patient has an epidural anesthetic]), abruption (which can cause uterine tenderness and tachycardia but is usually associated with vaginal bleeding), and any",
"    <span class=\"nowrap\">",
"     infection/inflammation",
"    </span>",
"    associated with fever. One report of two cases of sudden postpartum cardiovascular collapse, disseminated intravascular coagulation (DIC), and death hypothesized that IAI could mimic amniotic fluid embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Subclinical infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;When IAI is suspected in the absence of typical clinical signs (eg, in the context of preterm labor or membrane rupture), a variety of biophysical, serum,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    amniotic fluid tests may be used to diagnose subclinical IAI. These tests may also be used when clinical criteria are equivocal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Amniocentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amniocentesis for amniotic fluid culture is the best method for diagnosis of subclinical IAI in preterm gestations. This procedure has been used primarily in women with refractory preterm labor to determine whether continued tocolysis is appropriate and in women with preterm premature rupture of membranes to determine whether induction is indicated. Occasionally, amniocentesis is used to discriminate between IAI and other causes of abdominal pain, uterine tenderness, or maternal fever (eg, maternal viral syndrome, abruption, appendicitis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Culture of amniotic fluid remains the \"gold standard\" and most specific test for documentation of IAI, but is limited by the fact that it may take days to get definitive results. Several other tests, including Gram stain, glucose concentration, white blood cell concentration, leukocyte esterase level, and measurement of cytokines (eg, IL-6), ceramide lactoside, or short-chain organic acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/19\">",
"     19",
"    </a>",
"    ] suggestive of infection, can be obtained more rapidly. The majority of these tests have relatively low predictive value for a positive amniotic fluid culture (25 to 75 percent) and even lower ability to predict neonatal sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. IL-6 is classically one of the most sensitive tests for IAI, but at the expense of reduced specificity (ie, increased risk of falsely positive results). IL-6 is not being used clinically at this time.",
"   </p>",
"   <p>",
"    The following details are about selected tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gram stain is performed on an unspun specimen of amniotic fluid; centrifugation does not significantly improve the sensitivity of the technique. Twenty to 30 high power fields should be examined. The presence of any bacteria and leukocytes (at least six leukocytes per high-power field) is suspicious for infection.",
"     </li>",
"     <li>",
"      Glucose concentration is measured with an autoanalyzer (abnormal result &lt;15",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"     </li>",
"     <li>",
"      WBC concentration can be determined using a Coulter counter (abnormal result &gt;30",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ).",
"      </span>",
"     </li>",
"     <li>",
"      Leukocyte esterase activity is evaluated with Chemstrip 9 Reagent Strips (abnormal result = trace or greater).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with preterm labor, the combined result of positive gram stain, positive leukocyte esterase, low glucose concentration, and elevated WBC concentration has sensitivity of 90 percent and specificity of 80 percent for predicting positive results of amniotic fluid culture. However, since the prevalence of IAI is relatively low (about 10 percent), this combination of tests has a false positive rate of 67 percent, thus the clinician should use caution in acting prior to obtaining culture results, particularly when the intervention involves delivery of an immature fetus. In addition, an elevated WBC concentration is less predictive of infection if the amniocentesis is traumatic (defined as amniotic fluid containing &ge;1000",
"    <span class=\"nowrap\">",
"     RBCs/mm3)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinicians perform amniocentesis to exclude subclinical IAI in patients with preterm labor or cervical insufficiency before attempts are made to prolong pregnancy. We do not recommend routine amniocentesis in patients with preterm labor or cervical insufficiency because of the poor predictive value of the combined test, the 48-hour delay in obtaining definitive culture results, and the lack of data proving that this approach reduces",
"    <span class=\"nowrap\">",
"     maternal/neonatal",
"    </span>",
"    morbidity.",
"   </p>",
"   <p>",
"    Elevated cytokine levels in amniotic fluid and fetal blood are associated with infection, preterm birth, and systemic fetal inflammatory syndrome (see below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/6,19\">",
"     6,19",
"    </a>",
"    ]. Besides the invasive nature of specimen collection, the technical complexity of the assays, lack of standards across laboratories, and relatively high false positive rates currently limit this testing to research settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3143580\">",
"    <span class=\"h3\">",
"     Nonstress test and biophysical profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most fetuses exposed to IAI will have a normal amniotic fluid index, reactive nonstress testing (NST), and a normal biophysical profile (BPP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. With significant fetal involvement (defined by histologic evidence of funisitis or other fetal vasculitis), the fetus is more likely to develop abnormal biophysical testing, decreased fetal movement, amniotic fluid index &lt;5 cm, a nonreactive nonstress test, or a biophysical profile less than",
"    <span class=\"nowrap\">",
"     8/10.",
"    </span>",
"   </p>",
"   <p>",
"    A randomized trial involving 135 women with preterm membrane rupture randomly assigned to daily nonstress testing or biophysical profile scoring found that both modalities had poor sensitivity for infection (39 and 25 percent, respectively); specificities were 85 and 93 percent, respectively; and BPPs were significantly more costly than NSTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/26\">",
"     26",
"    </a>",
"    ]. This trial suggests that these methods are not useful for predicting infection (a negative test should not override a strong clinical suspicion of infection), although if clinical suspicion is low, a negative result may provide some reassurance concerning the absence of infection. Used with these caveats, the NST appears preferable to the BPP because it is less costly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3143587\">",
"    <span class=\"h3\">",
"     Inflammatory markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of maternal inflammatory response (eg, C-reactive protein &gt;2",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    is not useful for prediction of early IAI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/22,27,28\">",
"     22,27,28",
"    </a>",
"    ]. Novel proteomic biomarkers in the amniotic fluid or in the maternal serum are under investigation in an attempt to identify unique proteins diagnostic of subclinical IAI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Preliminary studies show promise in the diagnosis of early IAI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\", section on 'Proteomics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Vaginal pool glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to avoid invasive testing, one group studied whether vaginal pool amniotic fluid glucose concentration could be used to predict IAI in women with preterm PROM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/33\">",
"     33",
"    </a>",
"    ]. If the vaginal pool glucose was less than 5",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    the sensitivity, specificity, positive and negative predictive values for identifying women with a positive amniotic fluid culture were 47, 100, 100, and 67 percent, respectively. Although the sensitivity was low at this threshold, a positive test was a reliable predictor of IAI.",
"   </p>",
"   <p>",
"    Before vaginal pool glucose measurements can be recommended, further studies need to be performed to confirm these results and determine whether factors such as latency period, bleeding, medications, or recent sexual activity, could affect results. More importantly, studies will have to demonstrate that intervention for subclinical infection leads to improved neonatal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maternal outcomes in preterm pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Histological chorioamnionitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal and fetal immune response to IAI is manifested by inflammation of the chorioamnion (histologic chorioamnionitis) and umbilical cord (funisitis), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. While these histologic changes can result from noninfectious insults (hypoxic injury, trauma, meconium, allergens), subclinical or clinical infection, usually bacterial, is the most common cause. Histologic chorioamnionitis is present in 60 to 80 percent of placentas of deliveries less than 28 weeks, 40 to 50 percent of placentas of deliveries at 29 to 34 weeks, and 5 to 30 percent of placentas at deliveries greater than 34 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/36\">",
"     36",
"    </a>",
"    ]. Funisitis is almost always associated with chorioamnionitis, but is present in only 50 to 75 percent of placentas with chorioamnionitis.",
"   </p>",
"   <p>",
"    The clinical diagnosis of chorioamnionitis is not always confirmed by histological or microbiological studies. In one study of 139 pregnancies with clinical findings of chorioamnionitis, histologic examination of the placenta did not support the clinical diagnosis in approximately one-third of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/34\">",
"     34",
"    </a>",
"    ]. The investigators suggested that noninflammatory events (eg, epidural anesthesia, abruption) could be responsible for maternal fever, tachycardia, or uterine tenderness.",
"   </p>",
"   <p>",
"    Conversely, histologic evidence of placental inflammation may not always be associated with microbiological evidence of an infectious organism. The frequency of histologic chorioamnionitis is two to three times the incidence of clinical infection with positive bacterial cultures of the amniotic fluid or membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Negative cultures in the presence of histologic inflammation may be due to suboptimal microbiological techniques for fastidious organisms such as Mycoplasma sp, administration of intrapartum antibiotics, or a noninfection-related cause of placental inflammation. Therefore, placentas should be sent for pathologic evaluation in the setting of suspected IAI even without clinical signs and particularly among preterm births. Practitioners should keep in mind that occasionally negative pathologic results will be obtained in some cases of IAI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4089?source=see_link\">",
"     \"Placental infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MATERNAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of septic shock, coagulopathy, or adult respiratory distress syndrome related to IAI are low if treatment with broad spectrum antibiotics has been initiated. More common maternal complications include labor abnormalities, need for cesarean delivery, uterine atony, and postpartum hemorrhage. Bacteremia occurs in 5 to 10 percent of women with IAI, and is most common with IAI associated with group B streptococcus or Escherichia coli (bacteremia in 18 and 15 percent of cases, respectively). In addition, cesarean delivery in the presence of IAI increases the risk of surgical complications, such as hemorrhage, wound infection, pelvic abscess, thromboembolism, and endomyometritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/7,39\">",
"     7,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intrapartum fever with or without documented infection is associated with abnormal labor and increases in cesarean deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/7,40,41\">",
"     7,40,41",
"    </a>",
"    ]. The effect of intrapartum fever on labor was illustrated by a large retrospective series using multivariate analysis to control for potential confounders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/40\">",
"     40",
"    </a>",
"    ]. The authors found intrapartum fever was associated with an increased need for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    , epidural analgesia, and cesarean delivery, as well as an increased incidence of first and second stage labor abnormalities.",
"   </p>",
"   <p>",
"    The type of infection also plays a role. Women with persistent high-virulence organisms in their amniotic fluid have more labor abnormalities and more severe IAI than women with low-virulence organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiologic mechanisms for labor abnormalities related to IAI are poorly understood; often complicated by other factors (eg, epidural anesthesia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/42\">",
"     42",
"    </a>",
"    ]. However, the link between intrapartum fever and a two-fold increase in postpartum hemorrhage points to a decrease in myometrial contractility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/7,40,41\">",
"     7,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MATERNAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics should be instituted immediately following a diagnosis of IAI. We initiate antibiotics for presumed chorioamnionitis even if epidural fever cannot be excluded.",
"   </p>",
"   <p>",
"    Early administration of broad-spectrum antibiotic therapy reduces both maternal and neonatal infections and produces better results than postdelivery treatment of mother and baby (",
"    <a class=\"graphic graphic_table graphicRef60582 \" href=\"mobipreview.htm?35/58/36779\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. Often during labor, the diagnosis of IAI is not obvious; fever may be isolated and the presence of epidural analgesia (a frequent cause of intrapartum fever among nulliparous) may further confound the presentation. In such instances, consideration of risk factors (eg, parity, prolonged membrane rupture or labor, multiple digital examinations, etc) and individualization of care are reasonable, with the objective to promptly initiate antibiotics if the diagnosis becomes more certain. For example, an isolated low grade fever (&lt;101) may be closely monitored, but a high fever or a low fever in a patient with risk factors for infection should be treated.",
"   </p>",
"   <p>",
"    Administration of broad spectrum parenteral antibiotics with coverage for beta-lactamase producing aerobes and anaerobes is the preferred therapy of both chorioamnionitis and postpartum endometritis. There are few good comparative trials of antibiotic regimens on which to base treatment recommendations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The standard treatment of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      (2 g intravenously every six hours) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      (1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every eight hours for patients with normal renal function) is safe and effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/48\">",
"       48",
"      </a>",
"      ]. A single daily dose of gentamicin (5.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily) is equally effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/49\">",
"       49",
"      </a>",
"      ]. This dose does not result in toxic maternal levels (peak 18.2",
"      <span class=\"nowrap\">",
"       microg/mL",
"      </span>",
"      and &lt;2",
"      <span class=\"nowrap\">",
"       microg/mL",
"      </span>",
"      by 10 hours) and results in appropriate fetal serum levels (peak 6.9",
"      <span class=\"nowrap\">",
"       microg/mL);",
"      </span>",
"      fetal levels are lower with standard dosing (1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every eight hours: fetal level 2.9",
"      <span class=\"nowrap\">",
"       microg/mL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/50\">",
"       50",
"      </a>",
"      ]. Routine monitoring of gentamicin levels is not indicated for the otherwise healthy woman with chorioamnionitis.",
"     </li>",
"     <li>",
"      Some alternative antibiotic regimens include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      (3 grams intravenously every six hours)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      (3.1 grams intravenously every four hours)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"       cefoxitin",
"      </a>",
"      (2 grams intravenously every six hours).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaerobes play a major role in the pathogenesis of preterm birth, the amniotic fluid flora of IAI (",
"      <a class=\"graphic graphic_table graphicRef66106 \" href=\"mobipreview.htm?43/32/44555\">",
"       table 1",
"      </a>",
"      ), and complications associated with post-cesarean endometritis. The addition of anaerobic coverage has reduced failure rates of post-cesarean endometritis and, because of this finding, we add",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (900 mg intravenously) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg intravenously) to the primary antibiotic regimen if the patient is undergoing a cesarean delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6031413\">",
"    <span class=\"h3\">",
"     Penicillin-allergic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence-based data to guide the treatment of intraamniotic infection in penicillin allergic patients are lacking (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    ). At our institution, we substitute",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    1 g intravenously every 12 hours for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17031031\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of antibiotic therapy has not been determined conclusively. We suggest continuing intrapartum antibiotics for one additional postpartum dose. This approach is based on data from a few small randomized or observational trials of women treated for chorioamnionitis before delivery that compared the outcomes of women treated with no [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/51\">",
"     51",
"    </a>",
"    ] or one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/52-54\">",
"     52-54",
"    </a>",
"    ] postpartum dose of antibiotics with the outcomes of those who received multiple postpartum antibiotic doses. In all of these trials, postpartum treatment with multiple doses of antibiotics was not associated with a significant reduction in treatment failure (usually defined as persistent fever) compared with less intensive therapy.",
"   </p>",
"   <p>",
"    Some clinicians continue the administration of antibiotics after delivery until the patient is afebrile and asymptomatic at least 24 hours. This is a reasonable alternative approach, given the small number of subjects and postpartum febrile events in these trials and differences among the trials in patient characteristics and treatment regimens. In one study, patients most likely to benefit from this approach were those who underwent cesarean delivery since they had a higher prevalence of persistent fever after delivery (15 percent versus 1 percent after vaginal delivery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/54\">",
"     54",
"    </a>",
"    ]. Further study is needed.",
"   </p>",
"   <p>",
"    There is no evidence that oral antibiotics are needed after discontinuation of parenteral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of women with postpartum endometritis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5001458\">",
"    <span class=\"h2\">",
"     Antenatal corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is controversial whether clinical evidence of IAI should be a contraindication to maternal treatment with antenatal corticosteroids to enhance fetal pulmonary maturation. The theoretical concern is that this treatment will increase maternal or neonatal infectious morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/56\">",
"     56",
"    </a>",
"    ]. No reliable outcome data are available, as women with IAI have been excluded from randomized trials of antenatal corticosteroid therapy; however, data from observational studies suggest that steroid use may reduce neonatal morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/57\">",
"     57",
"    </a>",
"    ]. Additionally, there is no evidence that a course of steroid treatment enhances infection in women who are receiving broad-spectrum antibiotics, and there is some evidence that steroids may be beneficial for septic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/58\">",
"     58",
"    </a>",
"    ]. Therefore, we feel that antenatal steroids may be given together with appropriate broad spectrum antibiotics when delivery is undertaken at preterm viable gestational ages. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Timing and route of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some clinicians believe that the longer the fetus stays in an infected environment, the greater the likelihood of developing neonatal infection and short and long-term complications. This concern may contribute to the greater rate of cesarean birth. However, an urgent delivery does not appear to be warranted. Intrapartum antimicrobial therapy provides bactericidal concentrations of antibiotics to the fetus, membranes, and amniotic fluid within one-half to one hour after infusion. Since the average time between diagnosis of IAI and delivery is three to five hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/59,60\">",
"     59,60",
"    </a>",
"    ], it is unlikely that shortening this period will affect neonatal outcome if the fetus is receiving adequate antibiotic therapy transplacentally and labor is progressing. Finally, overall, there is no evidence that the duration of infection or labor correlates with adverse neonatal outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/7,60\">",
"     7,60",
"    </a>",
"    ]; therefore, cesarean delivery should be reserved for standard obstetrical indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Fetal heart rate monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of continuous electronic fetal monitoring is appropriate for detecting the development of fetal compromise due to villous edema, hyperthermic stress, fetal infection, or other factors. Although no particular pattern of periodic heart rate changes signifies fetal infection, a category III tracing (eg, one with absent variability and late decelerations) is predictive of fetal acidosis and poor short-term outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/61\">",
"     61",
"    </a>",
"    ] and should be cause for expedited delivery. Fetal tachycardia is common in the setting of IAI, but mild tachycardia alone (category II tracing) is not highly predictive of fetal acidemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38311?source=see_link\">",
"     \"Management of intrapartum category I, II, and III fetal heart rate tracings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FETAL AND NEONATAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perinatal morbidities and mortality related to IAI in term and preterm neonates include pneumonia, meningitis, and sepsis (",
"    <a class=\"graphic graphic_table graphicRef74267 \" href=\"mobipreview.htm?15/46/16108\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/15,62-66\">",
"     15,62-66",
"    </a>",
"    ]. Neonatal morbidity and mortality appears to be inversely related to gestational age at delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible mechanisms include villous edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/68\">",
"     68",
"    </a>",
"    ], funisitis, fetal vascular inflammation, fetal cardiac dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/69,70\">",
"     69,70",
"    </a>",
"    ], abruptio placentae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/71,72\">",
"     71,72",
"    </a>",
"    ], an increase in oxygen consumption related to hyperthermia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a primary endotoxin effect on the fetus. In animal models, maternal hyperthermia and subsequent hyperventilation leads to a reduction in uterine blood flow and fetal acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/73\">",
"     73",
"    </a>",
"    ]. In human studies, the combination of maternal fever and fetal acidosis conferred a 12.5 percent risk of neonatal encephalopathy (OR 94, 95% CI 29-307), and each of these factors appeared to have an independent effect, as well (fever OR 8.1, 95% CI 3.5-18.6; neonatal acidosis OR 11.5, 95% CI 5.0-26.5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/74\">",
"     74",
"    </a>",
"    ]. These observations support the adjunctive use of antipyretics in IAI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1009631952\">",
"    <span class=\"h2\">",
"     Newborn assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=see_link&amp;anchor=H5#H5\">",
"     \"Assessment of the newborn infant\", section on 'Risk factors for sepsis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6410?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of sepsis in term and late preterm infants\", section on 'Maternal and neonatal risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Neurodevelopmental outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have found that neurodevelopmental delay and cerebral palsy are potential long-term disabilities resulting from IAI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/1,74-91\">",
"     1,74-91",
"    </a>",
"    ]. Among infants weighing &lt;2000 g, IAI is associated with a lower mental developmental index (Bayley Scales), and children exposed to IAI in utero are less likely to develop normally than unexposed children (64 versus 80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/59\">",
"     59",
"    </a>",
"    ]. This relationship was illustrated by data from the Collaborative Perinatal Project of the National Institute of Neurological and Communicative Disorders and Stroke (NCPP) that showed chorioamnionitis was associated with a 4.8 fold increased risk of cerebral palsy (2.6 fold when limited to infants &gt;2500 g) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings have subsequently been reported by others. In 2003, a nested case-control study in a cohort of over 230,000 singleton infants born at &lt;36 weeks of gestation found that cerebral palsy could be attributed to chorioamnionitis in 11 percent of cases; in multivariable analysis the odds of developing cerebral palsy after a diagnosis of chorioamnionitis was OR 4.1, 95% CI 1.6-10.1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meta-analyses have confirmed a significant association as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/83,92\">",
"     83,92",
"    </a>",
"    ]. As an example, a meta-analysis evaluating the association between IAI (clinical chorioamnionitis)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histologic chorioamnionitis and periventricular leukomalacia (PVL)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebral palsy reported IAI was associated with both PVL (RR 3.0, 95% CI 2.2-4.0) and cerebral palsy (preterm neonates RR 1.9, 95% CI 1.4-2.5; term neonates RR 4.7; 95% CI 1.3-16.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/83\">",
"     83",
"    </a>",
"    ]. These complications were still observed, but at a slightly lower rate, with histologic chorioamnionitis: cerebral palsy (RR 1.6; 95% CI 0.9-2.7), PVL (RR 2.1, 95% CI 1.5-2.9). However, this analysis was limited by many potential biases, such as differences in the definitions of IAI, histologic chorioamnionitis, cerebral palsy, and PVL across studies; extent of blinding in determining exposure status; and whether the study controlled for potential confounders.",
"   </p>",
"   <p>",
"    Three mechanisms have been proposed to explain the association between IAI and neurodevelopmental disability: aberrant fetal cytokine response, asphyxia, and toxic injury by bacterial products.",
"   </p>",
"   <p>",
"    The term systemic fetal inflammatory syndrome (also known as fetal inflammatory response syndrome) refers to the fetal immune response to intrauterine infection and the consequences of this response: preterm labor, fetal growth restriction, severe neonatal morbidity, brain injury, and chronic lung disease in the child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/1,75-91\">",
"     1,75-91",
"    </a>",
"    ]. High levels of",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    cytokines, especially tumor necrosis factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/86\">",
"     86",
"    </a>",
"    ], appear to mediate the",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    brain injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/79,80,84,86,87\">",
"     79,80,84,86,87",
"    </a>",
"    ]. These inflammatory cytokines can cause cerebral ischemia and damage, ultimately leading to intraventricular hemorrhage and periventricular leukomalacia. An interesting pilot study in rats showed that intrapartum maternal treatment with an anti-inflammatory cytokine (eg, interleukin-10) could prevent severe cerebral injury in the pups of mothers with intrauterine infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis of spontaneous preterm birth\", section on 'Bacteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Funisitis and chorionic vasculitis appear to be the placental histological manifestations of fetal inflammatory response syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. Funisitis is an independent risk factor for a lower median Bayley psychomotor index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/93\">",
"     93",
"    </a>",
"    ]. Vasculitis probably reduces perfusion and adds hypoxic injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pulmonary outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical observation suggests that chorioamnionitis can enhance fetal lung maturation. Accelerated pulmonary maturation may be mediated by the systemic fetal inflammatory syndrome or directly by endotoxin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/94\">",
"     94",
"    </a>",
"    ]. However, these infants also appear predisposed to develop respiratory distress syndrome and bronchopulmonary dysplasia, possibly related to increased vulnerability of inflamed lung tissue to injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/48/42761/abstract/91,95,96\">",
"     91,95,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29345529\">",
"    <span class=\"h2\">",
"     Preterm gestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis of IAI is typically clinical and based upon the presence of maternal fever of greater than 38 degrees C (100.4 F)",
"      <strong>",
"       and",
"      </strong>",
"      at least two of the following conditions: maternal leukocytosis (greater than 15,000",
"      <span class=\"nowrap\">",
"       cells/cubic",
"      </span>",
"      millimeter), maternal tachycardia (greater than 100",
"      <span class=\"nowrap\">",
"       beats/min),",
"      </span>",
"      fetal tachycardia (greater than 160",
"      <span class=\"nowrap\">",
"       beats/min),",
"      </span>",
"      uterine tenderness, purulent amniotic fluid (often with foul odor). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Amniocentesis for amniotic fluid culture is the best method for diagnosis of subclinical IAI. If gram stain and leukocyte esterase are positive, glucose concentration is low (&lt;15",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      and WBC concentration is elevated (&gt;30",
"      <span class=\"nowrap\">",
"       cells/cubic",
"      </span>",
"      millimeter), then the sensitivity of the combined result for predicting a positive amniotic fluid culture is approximately 90 percent with specificity of 80 percent. However, given the low prevalence of IAI (about 10 percent), the false positive rate is 67 percent. Therefore, we do not recommend amniocentesis to diagnose subclinical infection in the routine management of patients with preterm labor or cervical insufficiency. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Amniocentesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29345536\">",
"    <span class=\"h2\">",
"     Term gestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis of IAI in term labor is typically based solely on fever &gt;38 degrees (100.4F). Maternal and fetal tachycardia typically accompany maternal hyperthermia and have not been shown prospectively to add to the accuracy of diagnosis. Maternal leukocytosis is less helpful after prolonged labor, which is associated with leukocytosis. Uterine tenderness often cannot be discerned, as the majority of fever in term labor occurs in the setting of epidural analgesia. A foul odor may be suggestive of infection if present, but is uncommon and poorly defined in term labor. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29345550\">",
"    <span class=\"h2\">",
"     All gestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal complications of IAI include bacteremia, labor abnormalities, need for cesarean delivery, and hemorrhage. In addition, cesarean delivery in the presence of IAI increases the risk of surgical complications, such as hemorrhage, wound infection, and endomyometritis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Maternal complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intrapartum exposure to fever, inflammation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      infection may cause long-term neurodevelopmental delay and cerebral palsy. This association is especially potent at term. At this time, there is no way to predict which infants exposed to IAI are at risk and no interventions have been shown to reduce neurodevelopmental morbidity. Studies of neuroprotective agents including antioxidants and antiinflammatories are ongoing. Continuous electronic fetal monitoring during labor is reasonable for observing the development of fetal compromise in cases of IAI. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Fetal and neonatal complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IAI cannot be cured without delivery. We suggest prompt induction or augmentation of labor, as appropriate, with cesarean delivery for standard obstetrical indications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Immediate (cesarean) delivery in the presence of reassuring intrapartum fetal testing and administration of antibiotics does not improve neonatal or maternal outcome. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Timing and route of delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IAI is a polymicrobial infection (",
"      <a class=\"graphic graphic_table graphicRef66106 \" href=\"mobipreview.htm?43/32/44555\">",
"       table 1",
"      </a>",
"      ). Broad spectrum antibiotics with known ability to cross the placenta should be initiated at diagnosis to minimize maternal and fetal morbidity. A typical regimen is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      (2 g intravenously every six hours) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      (1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously every eight hours for patients with normal renal function).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (900 mg intravenously) is added to this regimen to reduce postsurgical infections related to anaerobes in patients undergoing cesarean delivery. We suggest a single dose of antibiotics after delivery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest initiating antibiotics for presumed chorioamnionitis even if epidural fever cannot be excluded (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/1\">",
"      Cornette L. Fetal and neonatal inflammatory response and adverse outcome. Semin Fetal Neonatal Med 2004; 9:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/2\">",
"      Lieberman E, Lang J, Richardson DK, et al. Intrapartum maternal fever and neonatal outcome. Pediatrics 2000; 105:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/3\">",
"      Soper DE, Mayhall CG, Dalton HP. Risk factors for intraamniotic infection: a prospective epidemiologic study. Am J Obstet Gynecol 1989; 161:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/4\">",
"      Frigoletto FD Jr, Lieberman E, Lang JM, et al. A clinical trial of active management of labor. N Engl J Med 1995; 333:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/5\">",
"      Newton ER. Chorioamnionitis and intraamniotic infection. Clin Obstet Gynecol 1993; 36:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/6\">",
"      Yoon BH, Romero R, Moon JB, et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2001; 185:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/7\">",
"      Rouse DJ, Landon M, Leveno KJ, et al. The Maternal-Fetal Medicine Units cesarean registry: chorioamnionitis at term and its duration-relationship to outcomes. Am J Obstet Gynecol 2004; 191:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/8\">",
"      Newton ER, Prihoda TJ, Gibbs RS. Logistic regression analysis of risk factors for intra-amniotic infection. Obstet Gynecol 1989; 73:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/9\">",
"      Tran SH, Caughey AB, Musci TJ. Meconium-stained amniotic fluid is associated with puerperal infections. Am J Obstet Gynecol 2003; 189:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/10\">",
"      Seaward PG, Hannah ME, Myhr TL, et al. International Multicentre Term Prelabor Rupture of Membranes Study: evaluation of predictors of clinical chorioamnionitis and postpartum fever in patients with prelabor rupture of membranes at term. Am J Obstet Gynecol 1997; 177:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/11\">",
"      Cheng YW, Delaney SS, Hopkins LM, Caughey AB. The association between the length of first stage of labor, mode of delivery, and perinatal outcomes in women undergoing induction of labor. Am J Obstet Gynecol 2009; 201:477.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/12\">",
"      Park HS, Romero R, Lee SM, et al. Histologic chorioamnionitis is more common after spontaneous labor than after induced labor at term. Placenta 2010; 31:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/13\">",
"      Soper DE, Mayhall CG, Froggatt JW. Characterization and control of intraamniotic infection in an urban teaching hospital. Am J Obstet Gynecol 1996; 175:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/14\">",
"      Cahill AG, Duffy CR, Odibo AO, et al. Number of cervical examinations and risk of intrapartum maternal fever. Obstet Gynecol 2012; 119:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/15\">",
"      Sperling RS, Newton E, Gibbs RS. Intraamniotic infection in low-birth-weight infants. J Infect Dis 1988; 157:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/16\">",
"      Yoon BH, Romero R, Park JS, et al. Microbial invasion of the amniotic cavity with Ureaplasma urealyticum is associated with a robust host response in fetal, amniotic, and maternal compartments. Am J Obstet Gynecol 1998; 179:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/17\">",
"      Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev 2005; 18:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/18\">",
"      Romero R, Kadar N, Vaisbuch E, Hassan SS. Maternal death following cardiopulmonary collapse after delivery: amniotic fluid embolism or septic shock due to intrauterine infection? Am J Reprod Immunol 2010; 64:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/19\">",
"      Gomez R, Ghezzi F, Romero R, et al. Premature labor and intra-amniotic infection. Clinical aspects and role of the cytokines in diagnosis and pathophysiology. Clin Perinatol 1995; 22:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/20\">",
"      Gauthier DW, Meyer WJ. Comparison of gram stain, leukocyte esterase activity, and amniotic fluid glucose concentration in predicting amniotic fluid culture results in preterm premature rupture of membranes. Am J Obstet Gynecol 1992; 167:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/21\">",
"      Abdel-Razeq SS, Buhimschi IA, Bahtiyar MO, et al. Interpretation of amniotic fluid white blood cell count in \"bloody tap\" amniocenteses in women with symptoms of preterm labor. Obstet Gynecol 2010; 116:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/22\">",
"      Roussis P, Rosemond RL, Glass C, Boehm FH. Preterm premature rupture of membranes: detection of infection. Am J Obstet Gynecol 1991; 165:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/23\">",
"      Graham EM, Holcroft CJ, Rai KK, et al. Neonatal cerebral white matter injury in preterm infants is associated with culture positive infections and only rarely with metabolic acidosis. Am J Obstet Gynecol 2004; 191:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/24\">",
"      Del Valle GO, Joffe GM, Izquierdo LA, et al. The biophysical profile and the nonstress test: poor predictors of chorioamnionitis and fetal infection in prolonged preterm premature rupture of membranes. Obstet Gynecol 1992; 80:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/25\">",
"      Miller JM Jr, Kho MS, Brown HL, Gabert HA. Clinical chorioamnionitis is not predicted by an ultrasonic biophysical profile in patients with premature rupture of membranes. Obstet Gynecol 1990; 76:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/26\">",
"      Lewis DF, Adair CD, Weeks JW, et al. A randomized clinical trial of daily nonstress testing versus biophysical profile in the management of preterm premature rupture of membranes. Am J Obstet Gynecol 1999; 181:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/27\">",
"      Gojnic M, Fazlagic A, Pervulov M, et al. The significance of C-reactive protein in the diagnosis of fetal tachycardia and therapy of chorioamnionitis. Clin Exp Obstet Gynecol 2005; 32:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/28\">",
"      Yoon BH, Romero R, Shim JY, et al. C-reactive protein in umbilical cord blood: a simple and widely available clinical method to assess the risk of amniotic fluid infection and funisitis. J Matern Fetal Neonatal Med 2003; 14:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/29\">",
"      Gravett MG, Novy MJ, Rosenfeld RG, et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. JAMA 2004; 292:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/30\">",
"      Buhimschi IA, Christner R, Buhimschi CS. Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflammation. BJOG 2005; 112:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/31\">",
"      Buhimschi IA, Zambrano E, Pettker CM, et al. Using proteomic analysis of the human amniotic fluid to identify histologic chorioamnionitis. Obstet Gynecol 2008; 111:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/32\">",
"      Hitti J, Lapidus JA, Lu X, et al. Noninvasive diagnosis of intraamniotic infection: proteomic biomarkers in vaginal fluid. Am J Obstet Gynecol 2010; 203:32.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/33\">",
"      Buhimschi CS, Sfakianaki AK, Hamar BG, et al. A low vaginal \"pool\" amniotic fluid glucose measurement is a predictive but not a sensitive marker for infection in women with preterm premature rupture of membranes. Am J Obstet Gynecol 2006; 194:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/34\">",
"      Smulian JC, Shen-Schwarz S, Vintzileos AM, et al. Clinical chorioamnionitis and histologic placental inflammation. Obstet Gynecol 1999; 94:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/35\">",
"      Steel JH, O'donoghue K, Kennea NL, et al. Maternal origin of inflammatory leukocytes in preterm fetal membranes, shown by fluorescence in situ hybridisation. Placenta 2005; 26:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/36\">",
"      Lahra MM, Jeffery HE. A fetal response to chorioamnionitis is associated with early survival after preterm birth. Am J Obstet Gynecol 2004; 190:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/37\">",
"      Dong Y, St Clair PJ, Ramzy I, et al. A microbiologic and clinical study of placental inflammation at term. Obstet Gynecol 1987; 70:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/38\">",
"      Hillier SL, Martius J, Krohn M, et al. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/39\">",
"      Hauth JC, Gilstrap LC 3rd, Hankins GD, Connor KD. Term maternal and neonatal complications of acute chorioamnionitis. Obstet Gynecol 1985; 66:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/40\">",
"      Mark SP, Croughan-Minihane MS, Kilpatrick SJ. Chorioamnionitis and uterine function. Obstet Gynecol 2000; 95:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/41\">",
"      Satin AJ, Maberry MC, Leveno KJ, et al. Chorioamnionitis: a harbinger of dystocia. Obstet Gynecol 1992; 79:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/42\">",
"      Newton ER, Schroeder BC, Knape KG, Bennett BL. Epidural analgesia and uterine function. Obstet Gynecol 1995; 85:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/43\">",
"      Gibbs RS, Dinsmoor MJ, Newton ER, Ramamurthy RS. A randomized trial of intrapartum versus immediate postpartum treatment of women with intra-amniotic infection. Obstet Gynecol 1988; 72:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/44\">",
"      Sperling RS, Ramamurthy RS, Gibbs RS. A comparison of intrapartum versus immediate postpartum treatment of intra-amniotic infection. Obstet Gynecol 1987; 70:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/45\">",
"      Gilstrap LC 3rd, Leveno KJ, Cox SM, et al. Intrapartum treatment of acute chorioamnionitis: impact on neonatal sepsis. Am J Obstet Gynecol 1988; 159:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/46\">",
"      Maberry MC, Gilstrap LC 3rd. Intrapartum antibiotic therapy for suspected intraamniotic infection: impact on the fetus and neonate. Clin Obstet Gynecol 1991; 34:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/47\">",
"      Hopkins L, Smaill F. Antibiotic regimens for management of intraamniotic infection. Cochrane Database Syst Rev 2002; :CD003254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/48\">",
"      French LM, Smaill FM. Antibiotic regimens for endometritis after delivery. Cochrane Database Syst Rev 2004; :CD001067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/49\">",
"      Lyell DJ, Pullen K, Fuh K, et al. Daily compared with 8-hour gentamicin for the treatment of intrapartum chorioamnionitis: a randomized controlled trial. Obstet Gynecol 2010; 115:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/50\">",
"      Locksmith GJ, Chin A, Vu T, et al. High compared with standard gentamicin dosing for chorioamnionitis: a comparison of maternal and fetal serum drug levels. Obstet Gynecol 2005; 105:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/51\">",
"      Turnquest MA, How HY, Cook CR, et al. Chorioamnionitis: is continuation of antibiotic therapy necessary after cesarean section? Am J Obstet Gynecol 1998; 179:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/52\">",
"      Edwards RK, Duff P. Single additional dose postpartum therapy for women with chorioamnionitis. Obstet Gynecol 2003; 102:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/53\">",
"      Chapman SJ, Owen J. Randomized trial of single-dose versus multiple-dose cefotetan for the postpartum treatment of intrapartum chorioamnionitis. Am J Obstet Gynecol 1997; 177:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/54\">",
"      Black LP, Hinson L, Duff P. Limited course of antibiotic treatment for chorioamnionitis. Obstet Gynecol 2012; 119:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/55\">",
"      Dinsmoor MJ, Newton ER, Gibbs RS. A randomized, double-blind, placebo-controlled trial of oral antibiotic therapy following intravenous antibiotic therapy for postpartum endometritis. Obstet Gynecol 1991; 77:60.",
"     </a>",
"    </li>",
"    <li>",
"     Report on the Consensus Development Conference on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. U.S. Department of Health and Human Services, Public Health Service, NIH Pub No. 95-3784, November 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/57\">",
"      Been JV, Degraeuwe PL, Kramer BW, Zimmermann LJ. Antenatal steroids and neonatal outcome after chorioamnionitis: a meta-analysis. BJOG 2011; 118:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/58\">",
"      Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301:2362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/59\">",
"      Gibbs RS, Duff P. Progress in pathogenesis and management of clinical intraamniotic infection. Am J Obstet Gynecol 1991; 164:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/60\">",
"      Gilstrap LC 3rd, Cox SM. Acute chorioamnionitis. Obstet Gynecol Clin North Am 1989; 16:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/61\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol 2009; 114:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/62\">",
"      Yoder PR, Gibbs RS, Blanco JD, et al. A prospective, controlled study of maternal and perinatal outcome after intra-amniotic infection at term. Am J Obstet Gynecol 1983; 145:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/63\">",
"      Alexander JM, McIntire DM, Leveno KJ. Chorioamnionitis and the prognosis for term infants. Obstet Gynecol 1999; 94:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/64\">",
"      Morales WJ, Washington SR 3rd, Lazar AJ. The effect of chorioamnionitis on perinatal outcome in preterm gestation. J Perinatol 1987; 7:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/65\">",
"      Lau J, Magee F, Qiu Z, et al. Chorioamnionitis with a fetal inflammatory response is associated with higher neonatal mortality, morbidity, and resource use than chorioamnionitis displaying a maternal inflammatory response only. Am J Obstet Gynecol 2005; 193:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/66\">",
"      Aziz N, Cheng YW, Caughey AB. Neonatal outcomes in the setting of preterm premature rupture of membranes complicated by chorioamnionitis. J Matern Fetal Neonatal Med 2009; 22:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/67\">",
"      Ramsey PS, Lieman JM, Brumfield CG, Carlo W. Chorioamnionitis increases neonatal morbidity in pregnancies complicated by preterm premature rupture of membranes. Am J Obstet Gynecol 2005; 192:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/68\">",
"      Ilagan NB, Elias EG, Liang KC, et al. Perinatal and neonatal significance of bacteria-related placental villous edema. Acta Obstet Gynecol Scand 1990; 69:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/69\">",
"      Romero R, Espinoza J, Gon&ccedil;alves LF, et al. Fetal cardiac dysfunction in preterm premature rupture of membranes. J Matern Fetal Neonatal Med 2004; 16:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/70\">",
"      Di Naro E, Cromi A, Ghezzi F, et al. Myocardial dysfunction in fetuses exposed to intraamniotic infection: new insights from tissue Doppler and strain imaging. Am J Obstet Gynecol 2010; 203:459.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/71\">",
"      Rana A, Sawhney H, Gopalan S, et al. Abruptio placentae and chorioamnionitis-microbiological and histologic correlation. Acta Obstet Gynecol Scand 1999; 78:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/72\">",
"      Darby MJ, Caritis SN, Shen-Schwarz S. Placental abruption in the preterm gestation: an association with chorioamnionitis. Obstet Gynecol 1989; 74:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/73\">",
"      Kirshon B, Moise KJ Jr, Wasserstrum N. Effect of acetaminophen on fetal acid-base balance in chorioamnionitis. J Reprod Med 1989; 34:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/74\">",
"      Impey LW, Greenwood CE, Black RS, et al. The relationship between intrapartum maternal fever and neonatal acidosis as risk factors for neonatal encephalopathy. Am J Obstet Gynecol 2008; 198:49.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/75\">",
"      Gaudet LM, Smith GN. Cerebral palsy and chorioamnionitis: the inflammatory cytokine link. Obstet Gynecol Surv 2001; 56:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/76\">",
"      Gomez R, Romero R, Ghezzi F, et al. The fetal inflammatory response syndrome. Am J Obstet Gynecol 1998; 179:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/77\">",
"      Gilstrap LC 3rd, Ramin SM. Infection and cerebral palsy. Semin Perinatol 2000; 24:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/78\">",
"      Perlman JM. White matter injury in the preterm infant: an important determination of abnormal neurodevelopment outcome. Early Hum Dev 1998; 53:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/79\">",
"      Leviton A, Paneth N, Reuss ML, et al. Maternal infection, fetal inflammatory response, and brain damage in very low birth weight infants. Developmental Epidemiology Network Investigators. Pediatr Res 1999; 46:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/80\">",
"      Debillon T, Gras-Leguen C, V&eacute;rielle V, et al. Intrauterine infection induces programmed cell death in rabbit periventricular white matter. Pediatr Res 2000; 47:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/81\">",
"      Wu YW, Escobar GJ, Grether JK, et al. Chorioamnionitis and cerebral palsy in term and near-term infants. JAMA 2003; 290:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/82\">",
"      Nelson KB, Ellenberg JH. Antecedents of cerebral palsy. I. Univariate analysis of risks. Am J Dis Child 1985; 139:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/83\">",
"      Wu YW, Colford JM Jr. Chorioamnionitis as a risk factor for cerebral palsy: A meta-analysis. JAMA 2000; 284:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/84\">",
"      Yoon BH, Jun JK, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol 1997; 177:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/85\">",
"      Williams MC, O'Brien WF, Nelson RN, Spellacy WN. Histologic chorioamnionitis is associated with fetal growth restriction in term and preterm infants. Am J Obstet Gynecol 2000; 183:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/86\">",
"      Kadhim H, Tabarki B, Verellen G, et al. Inflammatory cytokines in the pathogenesis of periventricular leukomalacia. Neurology 2001; 56:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/87\">",
"      Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/88\">",
"      Rodts-Palenik S, Wyatt-Ashmead J, Pang Y, et al. Maternal infection-induced white matter injury is reduced by treatment with interleukin-10. Am J Obstet Gynecol 2004; 191:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/89\">",
"      Pacora P, Chaiworapongsa T, Maymon E, et al. Funisitis and chorionic vasculitis: the histological counterpart of the fetal inflammatory response syndrome. J Matern Fetal Neonatal Med 2002; 11:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/90\">",
"      Yoon BH, Romero R, Park JS, et al. The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis. Am J Obstet Gynecol 2000; 183:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/91\">",
"      Jobe, AH. Antenatal associations with lung maturation and infection. J Peri 2005; 25 suppl 2:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/92\">",
"      Shatrov JG, Birch SC, Lam LT, et al. Chorioamnionitis and cerebral palsy: a meta-analysis. Obstet Gynecol 2010; 116:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/93\">",
"      Mittendorf R, Montag AG, MacMillan W, et al. Components of the systemic fetal inflammatory response syndrome as predictors of impaired neurologic outcomes in children. Am J Obstet Gynecol 2003; 188:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/94\">",
"      Newnham JP, Moss TJ, Kramer BW, et al. The fetal maturational and inflammatory responses to different routes of endotoxin infusion in sheep. Am J Obstet Gynecol 2002; 186:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/95\">",
"      Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996; 97:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/48/42761/abstract/96\">",
"      Yoon BH, Romero R, Kim KS, et al. A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1999; 181:773.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6762 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-EFBF5593C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42761=[""].join("\n");
var outline_f41_48_42761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preterm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Term",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical IAI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1956327\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Subclinical infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3143580\">",
"      - Nonstress test and biophysical profile",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3143587\">",
"      - Inflammatory markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Vaginal pool glucose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Histological chorioamnionitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MATERNAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MATERNAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6031413\">",
"      - Penicillin-allergic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17031031\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5001458\">",
"      Antenatal corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Timing and route of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Fetal heart rate monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FETAL AND NEONATAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1009631952\">",
"      Newborn assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Neurodevelopmental outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pulmonary outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29345529\">",
"      Preterm gestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29345536\">",
"      Term gestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29345550\">",
"      All gestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6762\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6762|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/32/44555\" title=\"table 1\">",
"      Microbiology of IAI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/58/36779\" title=\"table 2\">",
"      Result of antibiotic Rx for IAI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/46/16108\" title=\"table 3\">",
"      Neonatal outcome with IAI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/21/24922?source=related_link\">",
"      Assessment of the newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6410?source=related_link\">",
"      Clinical features and diagnosis of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41768?source=related_link\">",
"      Epidemiology and etiology of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/26/38311?source=related_link\">",
"      Management of intrapartum category I, II, and III fetal heart rate tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4089?source=related_link\">",
"      Placental infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_48_42762="Intermediate case 18";
var content_f41_48_42762=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1274px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Intermediate case 18",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42762=[""].join("\n");
var outline_f41_48_42762=null;
var title_f41_48_42763="Revised Bethesda criteria";
var content_f41_48_42763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The revised Bethesda guidelines for testing colorectal tumors for microsatellite instability (MSI)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Tumors from individuals should be tested for MSI in the following situations:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1. Colorectal cancer diagnosed in a patient who is less than 50 years of age.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       2. Presence of synchronous, metachronous colorectal, or other HNPCC-associated tumors*, regardless of age.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       3. Colorectal cancer with the MSI-H&bull;-like histology&Delta; diagnosed in a patient who is less than 60 years of age&loz;.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       4. Colorectal cancer diagnosed in a patient with one or more first-degree relatives with an HNPCC-related tumor, with one of the cancers being diagnosed under age 50 years.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       5. Colorectal cancer diagnosed in a patient with two or more first- or second-degree relatives with HNPCC-related tumors, regardless of age.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Hereditary nonpolyposis colorectal cancer (HNPCC)-related tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, and brain (usually glioblastoma as seen in Turcot syndrome) tumors, sebaceous gland adenomas and keratocanthomas in Muir-Torre syndrome, and carcinoma of the small bowel.",
"     <br>",
"      &bull; MSI-H: microsatellite instability-high in tumors refers to changes in two or more of the five National Cancer Institute-recommended panels of microsatellite markers.",
"      <br>",
"       &Delta; Presence of tumor infiltrating lymphocytes. Crohn's-like lymphocytic reaction, mucinous/signet-ring differentiation, or medullary growth pattern.",
"       <br>",
"        &loz; There was no consensus among the Workshop participants on whether to include the age criteria in guideline 3 above; participants voted to keep less than 60 years of age in the guidelines.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Umar A, et al. J Natl Cancer Inst 2004; 96:261. Copyright &copy; 2004 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42763=[""].join("\n");
var outline_f41_48_42763=null;
var title_f41_48_42764="RECIST response criteria solid tumors";
var content_f41_48_42764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Response Evaluation Criteria in Solid Tumors (RECIST)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Response assessment",
"       </td>",
"       <td class=\"subtitle1\">",
"        RECIST guideline, version 1.0",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        RECIST guideline, version 1.1",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Target lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CR",
"       </td>",
"       <td>",
"        Disappearance of all target lesions",
"       </td>",
"       <td>",
"        Disappearance of all target lesions and reduction in the short axis measurement of all pathologic lymph nodes to &le;10 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PR",
"       </td>",
"       <td>",
"        &ge;30 percent decrease in the sum of the longest diameter of the target lesions compared with baseline",
"       </td>",
"       <td>",
"        &ge;30 percent decrease in the sum of the longest diameter of the target lesions compared with baseline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PD",
"       </td>",
"       <td>",
"        <p>",
"         &ge;20 percent increase in the sum of the longest diameter of the target lesions compared to the smallest sum of the longest diameter recorded since treatment started",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         The appearance of one of more new lesions",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         &ge;20 percent increase of at least 5 mm in the sum of the longest diameters of the target lesions compared with the smallest sum of the longest diameter recorded",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         The appearance of new lesions including those detected by FDG-PET",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SD",
"       </td>",
"       <td>",
"        Neither PR nor PD",
"       </td>",
"       <td>",
"        Neither PR nor PD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Non-target lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CR",
"       </td>",
"       <td>",
"        Disappearance of all non-target lesions and normalization of tumor marker levels",
"       </td>",
"       <td>",
"        Disappearance of all non-target lesions and normalization of tumor marker levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        IR, SD",
"       </td>",
"       <td>",
"        Persistence of one or more non-target lesions and/or the maintenance of tumor marker levels above normal limits",
"       </td>",
"       <td>",
"        Persistence of one or more non-target lesions and/or the maintenance of tumor marker levels above normal limits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PD",
"       </td>",
"       <td>",
"        Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions",
"       </td>",
"       <td>",
"        <p>",
"         The appearance of one of more new lesions or unequivocal progression",
"        </p>",
"        <p>",
"         If patient has measurable disease, an increase in the overall level, or substantial worsening in non-target lesions, such that tumor burden has increased, even if there is a SD or PR in target lesions",
"        </p>",
"        <p>",
"         If no measurable disease, an increase in the overall tumor burden comparable in magnitude to the increase that would be required to declare PD in measurable disease (eg, an increase in pleural effusions from trace to large, or an increase in lymphangitic disease from localized to widespread)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CR: complete response; IR: incomplete response; PD: progressive disease; SD: stable disease.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Therasse P, et al. J Natl Cancer Inst 2000; 92:205.",
"       </li>",
"       <li>",
"        Eisenhauer E, et al. Eur J Cancer 2009; 45:228.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42764=[""].join("\n");
var outline_f41_48_42764=null;
var title_f41_48_42765="Contents: Obesity";
var content_f41_48_42765=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/56/1934\">",
"       Endocrinology and Diabetes",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Obesity",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Obesity",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/28/15816\">",
"           Behavioral strategies in the treatment of obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/22/18789\">",
"           Determining body composition in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/47/38649\">",
"           Dietary carbohydrates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/9/8345\">",
"           Dietary therapy for obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/4/33866\">",
"           Drug therapy of obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/21/3418\">",
"           Etiology and natural history of obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/23/16758\">",
"           Ghrelin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/35/30266\">",
"           Health hazards associated with obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/52/34630\">",
"           Obesity and weight reduction in hypertension",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/45/13016\">",
"           Overview of therapy for obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/38/13929\">",
"           Pathogenesis of obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/50/13094\">",
"           Physiology of leptin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/2/32810\">",
"           Postoperative management of the critically ill obese patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/41/21144\">",
"           Role of physical activity and exercise in obese adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/20/12615\">",
"           Screening for and clinical evaluation of obesity in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/31/33274\">",
"           Surgical management of severe obesity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/11/29882\">",
"           The impact of obesity on fertility and pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-3F42C8DE9C-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f41_48_42765=[""].join("\n");
var outline_f41_48_42765=null;
var title_f41_48_42766="Docetaxel cisplatin and FU plus chemoRT HNC ver1";
var content_f41_48_42766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Docetaxel, cisplatin and fluorouracil induction chemotherapy followed by chemoradiotherapy for locally advanced, squamous cell carcinoma of the head and neck (TAX324)",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: Every 21 days for three cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Docetaxel",
"        </strong>",
"       </td>",
"       <td>",
"        75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline (NS) to a final concentration of 0.3 to 0.74 mg/mL and administer over 60 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cisplatin",
"        </strong>",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS and administer over 30 minutes to three hours. Do not administer with aluminum needles or IV sets.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        1000 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /day IV",
"       </td>",
"       <td>",
"        Dilute in 500 to 1000 mL 5 percent dextrose in water or NS and administer as a continuous infusion over 24 hours.",
"       </td>",
"       <td>",
"        Days 1 through 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        IV fluid to establish a urine flow of at least 100 mL/hour for two hours before and two hours after cisplatin administration. Total hydration of 2 to 3 liters NS on day 1 and 1 to 2 liters NS on day 2 to prevent nephrotoxicity. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with dexamethasone prior to docetaxel administration. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Prophylactic therapy with a fluoroquinolone antibiotic is indicated on days 5 to 15 of each cycle because of the high frequency of grade 3 or 4 neutropenia",
"        <sup>",
"         [1]",
"        </sup>",
"        . Primary prophylaxis with recombinant G-CSF was not permitted in the original protocol. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Docetaxel and cisplatin are irritants, but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Docetaxel should not be given if bilirubin is &gt;ULN, or if AST and/or ALT &gt;1.5 x ULN with AP &gt;2.5 x ULN",
"        <sup>",
"         [2]",
"        </sup>",
"        . Dose adjustments for FU may be needed for patients with hepatic impairment",
"        <sup>",
"         [2]",
"        </sup>",
"        . The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Such patients were excluded from the original trial",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC, differential, and platelet count on day 1 on each cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Creatinine and electrolytes on day 5 or 6 of each treatment cycle; additional hydration of 1 liter of NS is recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Basic metabolic panel, including creatinine and electrolytes, and liver function tests prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for neurotoxicity, diarrhea, and palmar plantar erythrodysesthesias prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Gastrointestinal toxicity:",
"        </strong>",
"        Doses of docetaxel and FU should be reduced for grade 3 or 4 diarrhea or mucositis",
"        <sup>",
"         [2]",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Toxicity",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Dose adjustment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Diarrhea grade 3",
"       </td>",
"       <td colspan=\"2\">",
"        First episode: reduce FU dose by 20 percent.",
"        <br/>",
"        Second episode: reduce FU dose by an additional 20 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Diarrhea grade 4",
"       </td>",
"       <td colspan=\"2\">",
"        First episode: reduce docetaxel and FU doses by 20 percent.",
"        <br/>",
"        Second episode: discontinue treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Stomatitis/mucositis grade 3",
"       </td>",
"       <td colspan=\"2\">",
"        First episode: reduce FU dose by 20 percent.",
"        <br/>",
"        Second episode: Stop FU only at all subsequent cycles.",
"        <br/>",
"        Third episode: reduce docetaxel dose by 20 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Stomatitis/mucositis grade 4",
"       </td>",
"       <td colspan=\"2\">",
"        First episode: stop FU only at all subsequent cycles.",
"        <br/>",
"        Second episode: reduce docetaxel dose by 20 percent.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\" colspan=\"4\">",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea, mucositis, and myelosuppression or severe, prolonged neutropenia and/or thrombocytopenia after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hepatotoxicity:",
"        </strong>",
"        Docetaxel should not be given if bilirubin is &gt;ULN, or if AST and/or ALT &gt;1.5 x ULN with AP &gt;2.5 x ULN",
"        <sup>",
"         [2]",
"        </sup>",
"        . For intracycle increases of AST/ALT &gt;2.5 to &le;5 x ULN and AP &le;2.5 x ULN,",
"        <strong>",
"         OR",
"        </strong>",
"        AST/ALT &gt;1.5 to &le;5 x ULN",
"        <strong>",
"         AND",
"        </strong>",
"        AP &gt;2.5 to &le;5 x ULN , docetaxel should be reduced by 20 percent. In case of AST/ALT &gt;5 x ULN",
"        <strong>",
"         AND/OR",
"        </strong>",
"        AP &gt;5 x ULN, docetaxel should be stopped",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Patients should not be retreated with docetaxel until the neutrophil count is &gt;1500 cells/mm",
"        <sup>",
"         3[2]",
"        </sup>",
"        . In the original protocol, G-CSF was allowed during the second and/or subsequent cycles in case of febrile neutropenia, or documented infection with neutropenia, or neutropenia lasting more than seven days. If an episode of febrile neutropenia, prolonged neutropenia, or neutropenic infection occurs, FDA guidelines suggest reduction of docetaxel dose from 75 to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . FDA-labeling recommends a docetaxel dose reduction from 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        for an episode of febrile neutropenia, prolonged neutropenia, or neutropenic infection. If subsequent episodes of complicated neutropenia occur, the docetaxel dose should be reduced further from 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        to 45 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        . In case of grade 4 thrombocytopenia, the docetaxel dose should be reduced from 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        to 60 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Nephrotoxicity:",
"        </strong>",
"        Hold cisplatin until serum creatinine &lt;1.5 mg/dL and/or blood urea nitrogen &lt;25 mg/dL. For grade &ge;2 nephrotoxicity during treatment (creatinine &gt;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &lt;60 mL/min. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        Neuropathy usually is seen with cumulative doses of cisplatin &gt;400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        , although there is marked interindividual variation. Reduce cisplatin dose 20 percent for grade 2 peripheral neuropathy and discontinue for grade 3 neuropathy",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Palmar plantar erythrodysesthesia:",
"        </strong>",
"        Hold FU for grade 2 or greater palmar plantar erythrodysesthesia, and reduce subsequent dose by 20 percent",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        For other grade 3 or worse toxicity except for alopecia and anemia, delay chemotherapy (maximum of two weeks) until resolution to &lt;grade 1, then restart if medically appropriate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ULN: upper limit of normal; AP: alkaline phosphatase; G-CSF: granulocyte colony-stimulating factors.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Posner MR, et al. N Engl J Med 2007; 357:1705.",
"      </li>",
"      <li>",
"       Taxotere (docetaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).",
"      </li>",
"      <li>",
"       Fluorouracil injection FDA-approved package insert US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 20, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42766=[""].join("\n");
var outline_f41_48_42766=null;
var title_f41_48_42767="TEE aortic dissection";
var content_f41_48_42767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Longitudinal TEE view of a spontaneous dissection of the descending thoracic aorta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    As opposed to aortic disruption, the dissection is characterized by the presence of a thin \"intimal flap\" (arrow) which delimits two distinct lumina. Typically, color Doppler depicts higher blood flow velocities in the true lumen (TL) than in the false lumen (FL). In this patient, the false lumen was not circulating and a thrombus formation was observed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of P Vignon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_48_42767=[""].join("\n");
var outline_f41_48_42767=null;
